WO2021104146A1 - 含三并环类衍生物的盐或晶型及其药物组合物 - Google Patents
含三并环类衍生物的盐或晶型及其药物组合物 Download PDFInfo
- Publication number
- WO2021104146A1 WO2021104146A1 PCT/CN2020/130035 CN2020130035W WO2021104146A1 WO 2021104146 A1 WO2021104146 A1 WO 2021104146A1 CN 2020130035 W CN2020130035 W CN 2020130035W WO 2021104146 A1 WO2021104146 A1 WO 2021104146A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- diffraction peaks
- amino
- ray powder
- imidazo
- Prior art date
Links
- 239000013078 crystal Chemical group 0.000 title claims abstract description 111
- 150000003839 salts Chemical group 0.000 title claims abstract description 77
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 163
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 239000003814 drug Substances 0.000 claims abstract description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 222
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 203
- -1 nitro, amino Chemical group 0.000 claims description 201
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 192
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 134
- 229940080818 propionamide Drugs 0.000 claims description 130
- 239000002253 acid Substances 0.000 claims description 126
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 120
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 118
- 229910052739 hydrogen Inorganic materials 0.000 claims description 113
- 239000001257 hydrogen Substances 0.000 claims description 113
- 239000000243 solution Substances 0.000 claims description 112
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 108
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 105
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 104
- 150000002431 hydrogen Chemical class 0.000 claims description 101
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 94
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 81
- 238000006243 chemical reaction Methods 0.000 claims description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 70
- 238000003756 stirring Methods 0.000 claims description 69
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 68
- 239000002904 solvent Substances 0.000 claims description 63
- 125000002393 azetidinyl group Chemical group 0.000 claims description 60
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 57
- 239000007787 solid Substances 0.000 claims description 55
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 53
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 51
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 51
- BZLVMXJERCGZMT-UHFFFAOYSA-N methyl tert-butyl ether Substances COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 51
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 47
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 46
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 46
- 239000003960 organic solvent Substances 0.000 claims description 45
- 125000003566 oxetanyl group Chemical group 0.000 claims description 40
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 39
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 33
- 229910052805 deuterium Inorganic materials 0.000 claims description 32
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 31
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 31
- 229910052731 fluorine Inorganic materials 0.000 claims description 31
- 239000011737 fluorine Substances 0.000 claims description 31
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 31
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 30
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 30
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 29
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 27
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 26
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 24
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 24
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 23
- 239000001530 fumaric acid Substances 0.000 claims description 23
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 22
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 22
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 22
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 235000002906 tartaric acid Nutrition 0.000 claims description 22
- 239000011975 tartaric acid Substances 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 239000012458 free base Substances 0.000 claims description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 20
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 20
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 19
- 239000000725 suspension Substances 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 16
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 16
- 150000001298 alcohols Chemical class 0.000 claims description 16
- 150000002170 ethers Chemical class 0.000 claims description 16
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 16
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 15
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 15
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 14
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 14
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 14
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 14
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 14
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 14
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 14
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 14
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 14
- 229910052794 bromium Inorganic materials 0.000 claims description 14
- 229930016911 cinnamic acid Natural products 0.000 claims description 14
- 235000013985 cinnamic acid Nutrition 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 14
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 14
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 14
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 14
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 14
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 14
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 14
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 14
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 13
- 229960005261 aspartic acid Drugs 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 12
- 235000011090 malic acid Nutrition 0.000 claims description 12
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 12
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 11
- 229960000583 acetic acid Drugs 0.000 claims description 11
- 150000001555 benzenes Chemical class 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 150000002576 ketones Chemical class 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 10
- 241000723346 Cinnamomum camphora Species 0.000 claims description 10
- 229960000846 camphor Drugs 0.000 claims description 10
- 229930008380 camphor Natural products 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 9
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 9
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims description 9
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001361 adipic acid Substances 0.000 claims description 8
- 229960000250 adipic acid Drugs 0.000 claims description 8
- 235000011037 adipic acid Nutrition 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 8
- 239000011976 maleic acid Substances 0.000 claims description 8
- 239000001630 malic acid Substances 0.000 claims description 8
- 229940099690 malic acid Drugs 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 150000002825 nitriles Chemical class 0.000 claims description 8
- 229940116315 oxalic acid Drugs 0.000 claims description 8
- 235000006408 oxalic acid Nutrition 0.000 claims description 8
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 8
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 7
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims description 7
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 7
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 7
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 7
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 claims description 7
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 claims description 7
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 7
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 claims description 7
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 7
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 7
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 7
- RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 claims description 7
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- 239000005639 Lauric acid Substances 0.000 claims description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 7
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000021314 Palmitic acid Nutrition 0.000 claims description 7
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims description 7
- 229960001171 acetohydroxamic acid Drugs 0.000 claims description 7
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 7
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 7
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 7
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 7
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 7
- 235000010350 erythorbic acid Nutrition 0.000 claims description 7
- 239000004318 erythorbic acid Substances 0.000 claims description 7
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 7
- 239000000174 gluconic acid Substances 0.000 claims description 7
- 229950006191 gluconic acid Drugs 0.000 claims description 7
- 235000012208 gluconic acid Nutrition 0.000 claims description 7
- 229940097043 glucuronic acid Drugs 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 229960002989 glutamic acid Drugs 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 7
- 229940071870 hydroiodic acid Drugs 0.000 claims description 7
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 7
- 229940045996 isethionic acid Drugs 0.000 claims description 7
- 229940026239 isoascorbic acid Drugs 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 229960000448 lactic acid Drugs 0.000 claims description 7
- 229940099563 lactobionic acid Drugs 0.000 claims description 7
- 229940033355 lauric acid Drugs 0.000 claims description 7
- 229960002510 mandelic acid Drugs 0.000 claims description 7
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 7
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 229910017604 nitric acid Inorganic materials 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 229960002446 octanoic acid Drugs 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 229960002969 oleic acid Drugs 0.000 claims description 7
- 229960005010 orotic acid Drugs 0.000 claims description 7
- 229940098695 palmitic acid Drugs 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000019260 propionic acid Nutrition 0.000 claims description 7
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 7
- 229960004889 salicylic acid Drugs 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 7
- 229960004319 trichloroacetic acid Drugs 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 229960002703 undecylenic acid Drugs 0.000 claims description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 6
- 229960005219 gentisic acid Drugs 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 125000005475 oxolanyl group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 5
- 229940124607 PI3Kα inhibitor Drugs 0.000 claims description 5
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 5
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 5
- 239000011550 stock solution Substances 0.000 claims description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 4
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940116353 sebacic acid Drugs 0.000 claims description 4
- 229960004274 stearic acid Drugs 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- IHKAGESSVVOIIU-UHFFFAOYSA-N (3-ethoxy-3-methoxypropyl) hypofluorite Chemical compound CCOC(OC)CCOF IHKAGESSVVOIIU-UHFFFAOYSA-N 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 239000012828 PI3K inhibitor Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 125000006000 trichloroethyl group Chemical group 0.000 claims description 3
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960004592 isopropanol Drugs 0.000 claims 19
- CIBMHJPPKCXONB-UHFFFAOYSA-N propane-2,2-diol Chemical compound CC(C)(O)O CIBMHJPPKCXONB-UHFFFAOYSA-N 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 58
- 239000012074 organic phase Substances 0.000 description 54
- 238000004440 column chromatography Methods 0.000 description 49
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 44
- 238000005481 NMR spectroscopy Methods 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 28
- 150000002460 imidazoles Chemical class 0.000 description 28
- 238000012360 testing method Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 229920006395 saturated elastomer Polymers 0.000 description 25
- 239000007864 aqueous solution Substances 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 229960001367 tartaric acid Drugs 0.000 description 18
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- SGEUNORSOZVTOL-CABZTGNLSA-N (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(OC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F SGEUNORSOZVTOL-CABZTGNLSA-N 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 235000019270 ammonium chloride Nutrition 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 238000001556 precipitation Methods 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 13
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 13
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 229960003767 alanine Drugs 0.000 description 10
- 239000012296 anti-solvent Substances 0.000 description 10
- 125000005605 benzo group Chemical group 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 10
- KPGYPWXVADQHRR-REOHCLBHSA-N (4S)-4-(difluoromethyl)-1,3-oxazolidin-2-one Chemical compound FC([C@H]1NC(OC1)=O)F KPGYPWXVADQHRR-REOHCLBHSA-N 0.000 description 9
- 102000038030 PI3Ks Human genes 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229910000160 potassium phosphate Inorganic materials 0.000 description 9
- 235000011009 potassium phosphates Nutrition 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 6
- IRYFOCPODANPMO-UHFFFAOYSA-N 3-bromo-2-fluoro-6-(1H-imidazol-2-yl)phenol Chemical compound BrC=1C(=C(C(=CC=1)C=1NC=CN=1)O)F IRYFOCPODANPMO-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- BCHBVHMSOBXQFC-UHFFFAOYSA-N 4-bromo-3-fluoro-2-hydroxybenzaldehyde Chemical compound Oc1c(F)c(Br)ccc1C=O BCHBVHMSOBXQFC-UHFFFAOYSA-N 0.000 description 6
- PYWGJFVEOGVKSP-UHFFFAOYSA-N 4-bromo-3-fluoro-2-methoxybenzaldehyde Chemical compound COC1=C(F)C(Br)=CC=C1C=O PYWGJFVEOGVKSP-UHFFFAOYSA-N 0.000 description 6
- SMHDMAYAZJZZHS-UHFFFAOYSA-N 9-bromo-2-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound C1COC2=CC(Br)=CC=C2C2=NC(I)=CN21 SMHDMAYAZJZZHS-UHFFFAOYSA-N 0.000 description 6
- NWXJJZHXRYPOQF-UHFFFAOYSA-N 9-bromo-8-fluoro-2,3-diiodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound BrC1=C(C2=C(C=3N(CCO2)C(=C(N=3)I)I)C=C1)F NWXJJZHXRYPOQF-UHFFFAOYSA-N 0.000 description 6
- QOADWPABIUUPRT-UHFFFAOYSA-N 9-bromo-8-fluoro-2-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound BrC1=C(C2=C(C=3N(CCO2)C=C(N=3)I)C=C1)F QOADWPABIUUPRT-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 229940124639 Selective inhibitor Drugs 0.000 description 6
- 239000012964 benzotriazole Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 229940095574 propionic acid Drugs 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 5
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 5
- ANBZWDBEKOZNHY-UHFFFAOYSA-N ethanol;oxalic acid Chemical compound CCO.OC(=O)C(O)=O ANBZWDBEKOZNHY-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 229940015043 glyoxal Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 238000012453 sprague-dawley rat model Methods 0.000 description 5
- UMURLIQHQSKULR-UHFFFAOYSA-N 1,3-oxazolidine-2-thione Chemical compound S=C1NCCO1 UMURLIQHQSKULR-UHFFFAOYSA-N 0.000 description 4
- WVJIWHPGKUTCCS-UHFFFAOYSA-N 9-bromo-8-fluoro-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound BrC1=C(C2=C(C=3N(CCO2)C=CN=3)C=C1)F WVJIWHPGKUTCCS-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229940116298 l- malic acid Drugs 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000012805 post-processing Methods 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- YWQRCWUFAFEJGI-MWLCHTKSSA-N (4R,5R)-3-benzyl-4-(hydroxymethyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(O[C@@H]([C@H]1CO)C)=O YWQRCWUFAFEJGI-MWLCHTKSSA-N 0.000 description 3
- PUJSAHFBGOOWDN-VIFPVBQESA-N (4S)-3-(9-bromo-3-fluoro-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-2-yl)-4-(difluoromethyl)-1,3-oxazolidin-2-one Chemical compound [C@H]1(C(F)F)N(C(=O)OC1)C=1N=C2C3=CC=C(Br)C=C3OCCN2C=1F PUJSAHFBGOOWDN-VIFPVBQESA-N 0.000 description 3
- JWZVEWZXOCOBNA-VIFPVBQESA-N (4S)-3-benzyl-4-(difluoromethyl)-1,3-oxazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(OC[C@H]1C(F)F)=O JWZVEWZXOCOBNA-VIFPVBQESA-N 0.000 description 3
- LGBUPCKKHLJVFJ-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=C(Br)C=C1C1=NC=CN1 LGBUPCKKHLJVFJ-UHFFFAOYSA-N 0.000 description 3
- KPGYPWXVADQHRR-UHFFFAOYSA-N 4-(difluoromethyl)-1,3-oxazolidin-2-one Chemical compound FC(F)C1COC(=O)N1 KPGYPWXVADQHRR-UHFFFAOYSA-N 0.000 description 3
- QHGYUSYTOROAJE-UHFFFAOYSA-N 5-bromo-2-(1H-imidazol-2-yl)aniline Chemical compound Nc1cc(Br)ccc1-c1ncc[nH]1 QHGYUSYTOROAJE-UHFFFAOYSA-N 0.000 description 3
- DMARJHVWFFDMSN-UHFFFAOYSA-N 5-bromo-2-(1H-imidazol-2-yl)phenol Chemical compound OC1=CC(Br)=CC=C1C1=NC=CN1 DMARJHVWFFDMSN-UHFFFAOYSA-N 0.000 description 3
- WWACSJBBTWYBDX-UHFFFAOYSA-N 5-bromo-2-(5-methyl-1H-imidazol-2-yl)phenol Chemical compound BrC=1C=CC(=C(C=1)O)C=1NC(=CN=1)C WWACSJBBTWYBDX-UHFFFAOYSA-N 0.000 description 3
- BQBLDYMYFVPCRJ-UHFFFAOYSA-N 9-bromo-2,3-diiodo-5,6-dihydroimidazo[1,2-d][1,4]benzothiazepine Chemical compound C1CSC2=C(C=CC(=C2)Br)C3=NC(=C(N31)I)I BQBLDYMYFVPCRJ-UHFFFAOYSA-N 0.000 description 3
- BOLGNRXJXPPVJO-UHFFFAOYSA-N 9-bromo-2,3-diiodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound C1COC2=CC(Br)=CC=C2C2=NC(I)=C(I)N21 BOLGNRXJXPPVJO-UHFFFAOYSA-N 0.000 description 3
- NIJTTWQBIYAWTE-UHFFFAOYSA-N 9-bromo-2-iodo-6,7-dihydro-5H-imidazo[1,2-d][1,4]benzodiazepine Chemical compound C1CN2C=C(N=C2C3=C(N1)C=C(C=C3)Br)I NIJTTWQBIYAWTE-UHFFFAOYSA-N 0.000 description 3
- ZRQDGMZVDFKYKI-UHFFFAOYSA-N 9-bromo-3-fluoro-2-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound BrC1=CC2=C(C=3N(CCO2)C(=C(N=3)I)F)C=C1 ZRQDGMZVDFKYKI-UHFFFAOYSA-N 0.000 description 3
- YFISESCRYOQTHO-UHFFFAOYSA-N 9-bromo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound C1COC2=CC(Br)=CC=C2C2=NC=CN21 YFISESCRYOQTHO-UHFFFAOYSA-N 0.000 description 3
- PJEMLHVYZBNVMN-ZYHUDNBSSA-N C(C1=CC=CC=C1)N1C(O[C@@H]([C@H]1C=O)C)=C=O Chemical compound C(C1=CC=CC=C1)N1C(O[C@@H]([C@H]1C=O)C)=C=O PJEMLHVYZBNVMN-ZYHUDNBSSA-N 0.000 description 3
- KGWCBNPSEYOPJJ-GWCFXTLKSA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CS3)C(F)F)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CS3)C(F)F)C3=C=O)=CN1CCO2 KGWCBNPSEYOPJJ-GWCFXTLKSA-N 0.000 description 3
- BUJFZLPGZRCFNR-KCJUWKMLSA-N C[C@@H]1[C@H](N(C(=C=O)O1)C2=CCCC=C2)C(F)F Chemical compound C[C@@H]1[C@H](N(C(=C=O)O1)C2=CCCC=C2)C(F)F BUJFZLPGZRCFNR-KCJUWKMLSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- PEZBJHXXIFFJBI-UHFFFAOYSA-N ethanol;phosphoric acid Chemical compound CCO.OP(O)(O)=O PEZBJHXXIFFJBI-UHFFFAOYSA-N 0.000 description 3
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102200085789 rs121913279 Human genes 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RQHVZUNHDJKBLO-OQPBUACISA-N (4S,5R)-3-(9-bromo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-2-yl)-4-(difluoromethyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound BrC1=CC2=C(C=3N(CCO2)C=C(N=3)N2C(O[C@@H]([C@H]2C(F)F)C)=O)C=C1 RQHVZUNHDJKBLO-OQPBUACISA-N 0.000 description 2
- GQMSHRCWCIHPNY-SCZZXKLOSA-N (4S,5R)-3-benzyl-4-(difluoromethyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(O[C@@H]([C@H]1C(F)F)C)=O GQMSHRCWCIHPNY-SCZZXKLOSA-N 0.000 description 2
- SCEXDRONCCYCBC-GBXIJSLDSA-N (4S,5R)-4-(difluoromethyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound FC([C@H]1NC(O[C@@H]1C)=O)F SCEXDRONCCYCBC-GBXIJSLDSA-N 0.000 description 2
- ZFKDWURAIPCLAI-SNVBAGLBSA-N (4r)-3-benzyl-4-(hydroxymethyl)-1,3-oxazolidin-2-one Chemical compound OC[C@@H]1COC(=O)N1CC1=CC=CC=C1 ZFKDWURAIPCLAI-SNVBAGLBSA-N 0.000 description 2
- RAQPZQAQMHUKTB-ODZAUARKSA-N (z)-but-2-enedioic acid;methanol Chemical compound OC.OC(=O)\C=C/C(O)=O RAQPZQAQMHUKTB-ODZAUARKSA-N 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 2
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- QYMDCNFJKKWRLR-UHFFFAOYSA-N 4-(difluoromethyl)-1,3-oxazolidine-2-thione Chemical compound C1C(NC(=S)O1)C(F)F QYMDCNFJKKWRLR-UHFFFAOYSA-N 0.000 description 2
- IMOLPSNRLZLWQR-UHFFFAOYSA-N 4-bromo-2,3-difluorobenzaldehyde Chemical compound FC1=C(F)C(C=O)=CC=C1Br IMOLPSNRLZLWQR-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- KOTVIGOUBOUAEJ-UHFFFAOYSA-N 9-bromo-2,3-diiodo-6,7-dihydro-5H-imidazo[1,2-d][1,4]benzodiazepine Chemical compound C1CN2C(=C(N=C2C3=C(N1)C=C(C=C3)Br)I)I KOTVIGOUBOUAEJ-UHFFFAOYSA-N 0.000 description 2
- QHHUDDCFXPIGBC-UHFFFAOYSA-N 9-bromo-2-iodo-3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound BrC1=CC2=C(C=3N(CCO2)C(=C(N=3)I)C)C=C1 QHHUDDCFXPIGBC-UHFFFAOYSA-N 0.000 description 2
- SUJKQBKGXPKLFX-UHFFFAOYSA-N 9-bromo-2-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzothiazepine Chemical compound C1CSC2=C(C=CC(=C2)Br)C3=NC(=CN31)I SUJKQBKGXPKLFX-UHFFFAOYSA-N 0.000 description 2
- HOFPSEKLMDUETJ-UHFFFAOYSA-N 9-bromo-3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine Chemical compound Cc1cnc2-c3ccc(Br)cc3OCCn12 HOFPSEKLMDUETJ-UHFFFAOYSA-N 0.000 description 2
- KOMYTUNWEDGUSQ-UHFFFAOYSA-N BrC1=CC=2C(=C3N(CCN2)CC=N3)C=C1 Chemical compound BrC1=CC=2C(=C3N(CCN2)CC=N3)C=C1 KOMYTUNWEDGUSQ-UHFFFAOYSA-N 0.000 description 2
- GZOWZCQXLDZNBT-UHFFFAOYSA-N C(C)O.C1(=CC=CC=2C(=CC=CC12)S(=O)(=O)O)S(=O)(=O)O Chemical compound C(C)O.C1(=CC=CC=2C(=CC=CC12)S(=O)(=O)O)S(=O)(=O)O GZOWZCQXLDZNBT-UHFFFAOYSA-N 0.000 description 2
- STRGFYFFKRHTKW-UHFFFAOYSA-N CCS(=O)(=O)O.CO Chemical compound CCS(=O)(=O)O.CO STRGFYFFKRHTKW-UHFFFAOYSA-N 0.000 description 2
- RECVTWUQTUJKGY-LBPRGKRZSA-N CN1C(=C=O)[C@H](N(C1=C=O)C2=CCCC=C2)C(F)F Chemical compound CN1C(=C=O)[C@H](N(C1=C=O)C2=CCCC=C2)C(F)F RECVTWUQTUJKGY-LBPRGKRZSA-N 0.000 description 2
- ZKTTXNARYOVVHC-CMPLNLGQSA-N CO[C@@H]1C[C@H](N(C1=C=O)C2=CCCC=C2)C(F)F Chemical compound CO[C@@H]1C[C@H](N(C1=C=O)C2=CCCC=C2)C(F)F ZKTTXNARYOVVHC-CMPLNLGQSA-N 0.000 description 2
- ZKTTXNARYOVVHC-JQWIXIFHSA-N CO[C@H]1C[C@H](N(C1=C=O)C2=CCCC=C2)C(F)F Chemical compound CO[C@H]1C[C@H](N(C1=C=O)C2=CCCC=C2)C(F)F ZKTTXNARYOVVHC-JQWIXIFHSA-N 0.000 description 2
- QPDYEJRFLRACFB-APPDUMDISA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@H](C(F)F)C3(COC3)O3)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@H](C(F)F)C3(COC3)O3)C3=C=O)=CN1CCO2 QPDYEJRFLRACFB-APPDUMDISA-N 0.000 description 2
- MBSPTXZYMZIBAL-XINAWCOVSA-N C[C@H]([C@@H](C(OC)=O)N1)OC1=C=O Chemical compound C[C@H]([C@@H](C(OC)=O)N1)OC1=C=O MBSPTXZYMZIBAL-XINAWCOVSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- TXZAIUNUKTYKEW-UHFFFAOYSA-N benzenesulfonic acid ethanol Chemical compound C(C)O.C(C)O.C1(=CC=CC=C1)S(=O)(=O)O TXZAIUNUKTYKEW-UHFFFAOYSA-N 0.000 description 2
- BDEHJCWCPMTAPO-UHFFFAOYSA-N benzenesulfonic acid;methanol Chemical compound OC.OS(=O)(=O)C1=CC=CC=C1 BDEHJCWCPMTAPO-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- XETRDYSPPPDVAB-UHFFFAOYSA-N butan-1-ol;propan-1-ol Chemical compound CCCO.CCCCO XETRDYSPPPDVAB-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
- JVUXIJBCBXCHMF-JTQLQIEISA-N (4R)-3-(9-bromo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-2-yl)-4-(difluoromethyl)-1,3-thiazolidin-2-one Chemical compound BrC1=CC2=C(C=3N(CCO2)C=C(N=3)N2C(SC[C@H]2C(F)F)=O)C=C1 JVUXIJBCBXCHMF-JTQLQIEISA-N 0.000 description 1
- RWUUCIPUCLWVIS-VIFPVBQESA-N (4R)-4-(difluoromethyl)-3-(8-fluoro-9-iodo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-2-yl)-1,3-thiazolidin-2-one Chemical compound [C@H]1(C(F)F)N(C(=O)SC1)C=1N=C2C3=CC=C(I)C(F)=C3OCCN2C=1 RWUUCIPUCLWVIS-VIFPVBQESA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- CAQZTSCRGMRSHX-ODZAUARKSA-N (z)-but-2-enedioic acid;ethanol Chemical compound CCO.OC(=O)\C=C/C(O)=O CAQZTSCRGMRSHX-ODZAUARKSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- VWIIJDNADIEEDB-UHFFFAOYSA-N 3-methyl-1,3-oxazolidin-2-one Chemical compound CN1CCOC1=O VWIIJDNADIEEDB-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- AOFNHBPTGRBFFX-UHFFFAOYSA-N 4-(difluoromethyl)-1,3-thiazolidin-2-one Chemical compound C1C(NC(=O)S1)C(F)F AOFNHBPTGRBFFX-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- HXTWKHXDFATMSP-UHFFFAOYSA-N 4-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC(Br)=CC=C1C=O HXTWKHXDFATMSP-UHFFFAOYSA-N 0.000 description 1
- MMFGGDVQLQQQRX-UHFFFAOYSA-N 5-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC=C(Br)C=C1C=O MMFGGDVQLQQQRX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CVTUBSIWUPNCKD-UHFFFAOYSA-N 9-bromo-5,6-dihydroimidazo[1,2-d][1,4]benzothiazepine Chemical compound C1CSC2=C(C=CC(=C2)Br)C3=NC=CN31 CVTUBSIWUPNCKD-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 241000143437 Aciculosporium take Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- SQTDUQZGFINJFK-UHFFFAOYSA-N BrC1=CC=2C(=C3N(CCN2)CC(=N3)I)C=C1 Chemical compound BrC1=CC=2C(=C3N(CCN2)CC(=N3)I)C=C1 SQTDUQZGFINJFK-UHFFFAOYSA-N 0.000 description 1
- KHNMBOFMIHGTKJ-SKDRFNHKSA-N C(C1=CC=CC=C1)N1C(O[C@@H]([C@H]1C(=O)O)C)=C=O Chemical compound C(C1=CC=CC=C1)N1C(O[C@@H]([C@H]1C(=O)O)C)=C=O KHNMBOFMIHGTKJ-SKDRFNHKSA-N 0.000 description 1
- NPQFXSYHRNGZGD-KBPBESRZSA-N C1CN([C@@H]1C(=O)N)C2=CC3=C(C=C2)C4=NC(=CN4CCO3)N5[C@@H](COC5=C=O)C(F)F Chemical compound C1CN([C@@H]1C(=O)N)C2=CC3=C(C=C2)C4=NC(=CN4CCO3)N5[C@@H](COC5=C=O)C(F)F NPQFXSYHRNGZGD-KBPBESRZSA-N 0.000 description 1
- RDEABEMBLSEKSQ-HZMBPMFUSA-N C[C@@H](C(N)=O)NC(C(C#N)=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C(C#N)=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=CN1CCO2 RDEABEMBLSEKSQ-HZMBPMFUSA-N 0.000 description 1
- YALXBIWPIVRBDT-FZMZJTMJSA-N C[C@@H](C(N)=O)NC(C(C)=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C(C)=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=CN1CCO2 YALXBIWPIVRBDT-FZMZJTMJSA-N 0.000 description 1
- HCZVZHGXZSTRNW-FZMZJTMJSA-N C[C@@H](C(N)=O)NC(C=C1)=C(C)C2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=C(C)C2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=CN1CCO2 HCZVZHGXZSTRNW-FZMZJTMJSA-N 0.000 description 1
- KBAZAOYQNRUDHG-NHYWBVRUSA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CC3)C(F)F)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CC3)C(F)F)C3=C=O)=CN1CCO2 KBAZAOYQNRUDHG-NHYWBVRUSA-N 0.000 description 1
- XMANQLWEQRENPS-GWCFXTLKSA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CN3)C(F)F)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CN3)C(F)F)C3=C=O)=CN1CCO2 XMANQLWEQRENPS-GWCFXTLKSA-N 0.000 description 1
- SVWDNRJVEAXPFE-HZMBPMFUSA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=C(C#N)N1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=C(C#N)N1CCO2 SVWDNRJVEAXPFE-HZMBPMFUSA-N 0.000 description 1
- LCWIQDQGMSYFLJ-HZMBPMFUSA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=C(C)N1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@@H](CO3)C(F)F)C3=C=O)=C(C)N1CCO2 LCWIQDQGMSYFLJ-HZMBPMFUSA-N 0.000 description 1
- LTEHRDOPWVIEEM-APPDUMDISA-N C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@H](C(F)F)C3(CC3)O3)C3=C=O)=CN1CCO2 Chemical compound C[C@@H](C(N)=O)NC(C=C1)=CC2=C1C1=NC(N([C@H](C(F)F)C3(CC3)O3)C3=C=O)=CN1CCO2 LTEHRDOPWVIEEM-APPDUMDISA-N 0.000 description 1
- HPIMWBDYYRTTMH-HZMBPMFUSA-N C[C@@H](C(N)=O)NC(C=CC1=C2OCCN3C1=NC(N([C@@H](CO1)C(F)F)C1=C=O)=C3)=C2C#N Chemical compound C[C@@H](C(N)=O)NC(C=CC1=C2OCCN3C1=NC(N([C@@H](CO1)C(F)F)C1=C=O)=C3)=C2C#N HPIMWBDYYRTTMH-HZMBPMFUSA-N 0.000 description 1
- KTDWQFPZQBLNIO-CABZTGNLSA-N C[C@@H](C(N)=O)NC(C=CC1=C2OCCN3C1=NC(N([C@@H](CS1)C(F)F)C1=C=O)=C3)=C2F Chemical compound C[C@@H](C(N)=O)NC(C=CC1=C2OCCN3C1=NC(N([C@@H](CS1)C(F)F)C1=C=O)=C3)=C2F KTDWQFPZQBLNIO-CABZTGNLSA-N 0.000 description 1
- UOQNOZUTUIFWIA-GWCFXTLKSA-N C[C@@H](C(N)=O)NC1=CC(OCCN2C3=NC(N([C@@H](CO4)C(F)F)C4=C=O)=C2)=C3C(C#N)=C1 Chemical compound C[C@@H](C(N)=O)NC1=CC(OCCN2C3=NC(N([C@@H](CO4)C(F)F)C4=C=O)=C2)=C3C(C#N)=C1 UOQNOZUTUIFWIA-GWCFXTLKSA-N 0.000 description 1
- JCXWOAZCFZQIRA-AAEUAGOBSA-N C[C@@H](C(N)=O)NC1=CC(OCCN2C3=NC(N([C@@H](CO4)C(F)F)C4=C=O)=C2)=C3C(C)=C1 Chemical compound C[C@@H](C(N)=O)NC1=CC(OCCN2C3=NC(N([C@@H](CO4)C(F)F)C4=C=O)=C2)=C3C(C)=C1 JCXWOAZCFZQIRA-AAEUAGOBSA-N 0.000 description 1
- XHJAFANZUDBMOZ-MFKMUULPSA-N C[C@@H]1[C@H](N(C(=C=O)O1)CC2=CC=CC=C2)C(=O)OC Chemical compound C[C@@H]1[C@H](N(C(=C=O)O1)CC2=CC=CC=C2)C(=O)OC XHJAFANZUDBMOZ-MFKMUULPSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LKSYKCXDNWLKKI-ZDUSSCGKSA-N FC([C@H]1N(C(OC1)=C=O)C=1N=C2N(CCOC3=C2C=CC(=C3)NC(C(=O)N)(C)C)C1)F Chemical compound FC([C@H]1N(C(OC1)=C=O)C=1N=C2N(CCOC3=C2C=CC(=C3)NC(C(=O)N)(C)C)C1)F LKSYKCXDNWLKKI-ZDUSSCGKSA-N 0.000 description 1
- AMMHCKRYRPQNAU-KBPBESRZSA-N FC([C@H]1N(C(SC1)=C=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)COC)C1)F Chemical compound FC([C@H]1N(C(SC1)=C=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)COC)C1)F AMMHCKRYRPQNAU-KBPBESRZSA-N 0.000 description 1
- 241000883306 Huso huso Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000004321 azepin-2-yl group Chemical group [H]N1C([H])=C([H])C([H])=C([H])C([H])=C1* 0.000 description 1
- KKCWBKUOPJMUQV-UHFFFAOYSA-N azetidine-2-carboxamide Chemical compound NC(=O)C1CCN1 KKCWBKUOPJMUQV-UHFFFAOYSA-N 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 229940003092 decanoic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NJYYWQHQUOODDL-UHFFFAOYSA-N oxetane-3-carboxamide Chemical compound NC(=O)C1COC1 NJYYWQHQUOODDL-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- UDMDNOFKRFLVIA-UHFFFAOYSA-N propanamide sulfuric acid Chemical compound S(=O)(=O)(O)O.C(CC)(=O)N UDMDNOFKRFLVIA-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 229940120731 pyruvaldehyde Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the invention belongs to the field of drug synthesis, and specifically relates to a preparation method and application of a salt containing a triacyl derivative and a crystal form thereof.
- the phosphatidylinositol 3-kinase (PI3K) protein family is divided into four categories: I, II, III, and IV, which are involved in the regulation of cell growth, proliferation, differentiation, survival, and glucose metabolism.
- the four types of PI3K proteins have different structures and functions. Among them, the most widely studied is type I PI3K. This type of PI3K is divided into four subtypes: PI3K ⁇ , PI3K ⁇ , PI3K ⁇ , and PI3K ⁇ . Among them, PI3K ⁇ has activating mutations and expansions in many tumors. Increase is closely related to the occurrence and development of tumors.
- PI3K ⁇ can activate platelets and play an important role in the occurrence and development of thrombosis and other diseases.
- PI3K ⁇ and PI3K ⁇ are mainly expressed in the blood system and are closely related to the immune system and inflammation.
- PI3K ⁇ is closely related to blood pressure stability and smooth muscle contraction.
- PI3K ⁇ has activating mutations and amplifications in a variety of tumors, and is the driving factor leading to tumorigenesis.
- PI3K ⁇ is a heterodimer composed of p110 catalytic subunit and p85 regulatory subunit.
- PI3K ⁇ is activated by receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCR). After activation, it catalyzes phosphatidylinositol 2 phosphate (PIP2) to produce phosphatidylinositol 3 phosphate (PIP3), and PIP3 can be further activated Protein kinase B (PKB, also known as AKT) and its downstream signaling pathways.
- RTKs receptor tyrosine kinases
- GPCR G protein-coupled receptors
- EGF epidermal growth factor
- FGF fibroblast growth factor
- VEGF vascular endothelial growth factor
- HGF hepatocyte growth factor
- insulin can activate PI3K ⁇ , thereby activating downstream cell proliferation signals Pathway, the abnormal activation of PI3K ⁇ can lead to rapid cell proliferation, which can lead to tumorigenesis.
- PI3K ⁇ has always been an important target for tumor drug research and development, but because most of the compounds are broad-spectrum inhibitors of PI3Ks, clinical research has caused large side effects, which severely limits the development of PI3Ks inhibitors.
- Current studies have determined that most of the side effects of PI3Ks broad-spectrum inhibitors are caused by the inhibition of PI3K ⁇ , PI3K ⁇ and PI3K ⁇ subtypes.
- PI3K ⁇ plays an important role in the side effects of thrombocytopenia and thrombosis.
- PI3K ⁇ inhibition can lead to immune system abnormalities. Autoimmune and infectious toxicity such as pneumonia, hepatitis, and diarrhea/enteritis are closely related to the inhibition of PI3K ⁇ targets.
- PI3K ⁇ is closely related to blood pressure stability and smooth muscle contraction, and is the main target that causes the side effects of hypertension. Therefore, the development of highly active and highly selective PI3K ⁇ inhibitors can further improve the anti-tumor effect of PI3K ⁇ inhibitors and reduce or eliminate serious side effects such as inflammation, thrombocytopenia and hypertension caused by other subtypes.
- the PI3K ⁇ selective inhibitor BYL-719 developed by Novartis is currently in phase III clinical research
- the PI3K ⁇ selective inhibitor MLN1117 developed by Takeda has entered phase II clinical research
- the selective inhibitor GDC-0077 developed by Genentech has also In the clinical phase I research stage.
- PI3K ⁇ selective inhibitors can be used to treat a variety of multiple tumors with PI3K ⁇ activating mutations or amplifications, and have great clinical application value.
- the PCT patent (application number: PCT/CN2019/088788 and PCT/CN2019/104558) of Jiangsu Hausen Pharmaceutical Group Co., Ltd. discloses a series of structures of inhibitors containing tricyclic derivatives.
- the present invention In order to make the product easy to handle, filter and dry, and to improve the solubility of the product, and to seek suitable features such as easy storage, long-term product stability and high bioavailability, the present invention has conducted a comprehensive study on the salts of the above substances, and is committed to obtaining the most suitable salt. And crystal form.
- the object of the present invention is to provide an acid addition salt represented by the general formula (I), the structure of which is as follows:
- W is selected from -O-, -S- or -NR aa -;
- G is selected from -O-, -S-, -CR aa R bb -or -NR aa -;
- R 1 and R 1 ' are selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkane Group, cyano substituted C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl, 5-10 membered heteroaryl, -(CH 2 ) n R cc , -(CH 2 ) n OR cc or -CR aa R bb OR cc ;
- R 1 and R 1 ' are connected to form a C 3-8 cycloalkyl or 3-8 membered heterocyclic group, wherein the C 3-8 cycloalkyl or 3-8 membered heterocyclic group is optionally further Hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3-8 cycloalkane One or more substituents in the group, 3-8 membered heterocyclic group, C 6-10 aryl group and 5-10 membered heteroaryl group;
- R 2 is selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3 -8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl or -(CH 2 ) n OR cc ;
- R 3 and R 3 ' are selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkane Group, C 3-8 cycloalkyl group, 3-8 membered heterocyclic group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 and R 3 ' are connected to form an oxo group, a C 3-8 cycloalkyl group or a 3-8 membered heterocyclic group, wherein the C 3-8 cycloalkyl group or a 3-8 membered heterocyclic group ,
- R 4 is selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3 -8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 5 is selected from hydrogen, deuterium, C 1-6 alkyl or C 1-6 haloalkyl
- R 1 or R 1 ' is connected with R 5 to form a 3-8 membered heterocyclic group, wherein the 3-8 membered heterocyclic group is optionally further substituted by hydrogen, deuterium, cyano, halogen, nitro, or amino.
- R aa , R bb and R cc are each independently selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl;
- M is an inorganic acid or an organic acid, wherein the inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid or phosphoric acid; the organic acid is selected from 2,5-dihydroxybenzoic acid, 1- Hydroxy-2-naphthoic acid, acetic acid, dichloroacetic acid, trichloroacetic acid, acetohydroxamic acid, adipic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, benzoic acid, 4-acetylaminobenzoic acid, 4-amino Benzoic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclohexane sulfamic acid, camphor sulfonic acid, aspartic acid, camphor acid, gluconic acid, glucuronic acid, glutamic acid,
- n is an integer from 0 to 3;
- x is an integer from 0 to 3;
- y is an integer of 1-5, preferably an integer of 1-3, and more preferably 1.
- R 1 and R 1 ' are selected from hydrogen, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, 3-8 membered heterocyclyl, -( CH 2 ) n OR cc or -CR aa R bb OR cc , preferably hydrogen, C 1-3 alkyl, C 1-3 hydroxyalkyl, C 1-3 haloalkyl, C 1-3 alkoxy, 3- 6-membered heterocyclic group, -(CH 2 ) n OR cc or -CR aa R bb OR cc , more preferably hydrogen, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy Group, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl,
- R 2 is selected from hydrogen, C 1-6 alkyl, halogen, cyano or -(CH 2 ) n OR cc , preferably hydrogen, C 1-3 alkyl, halogen, cyano or -(CH 2 ) n OR cc , More preferably hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, fluorine, chlorine, bromine or cyano, further preferably hydrogen, fluorine, methyl, methoxy or cyano ;
- any two connected R 2 form a substituted or unsubstituted C 3-6 cycloalkyl group or a substituted or unsubstituted 3-6 membered heterocyclic group, preferably a substituted or unsubstituted C 3-6 cycloalkyl group Or substituted or unsubstituted 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxecyclopropyl , Oxetanyl, oxolanyl, oxanyl, azetidinyl, azetidinyl, azetidinyl, azetidinyl, more preferably cyclobutyl, cyclopentyl , 1,3-Dioxopentyl or 1,3-dioxyl.
- R 3 and R 3 ' are selected from hydrogen, C 1-6 alkyl, halogen, cyano or C 1-6 alkoxy, preferably hydrogen, C 1-3 alkyl, halogen, cyano or C 1-3 alkane Oxy group, more preferably hydrogen, methyl, ethyl, propyl, fluorine, chlorine, bromine, cyano, methoxy, ethoxy or propoxy, further preferably hydrogen, fluorine, methyl, methoxy or Cyano
- R 3 and R 3 ' are connected to form an oxo group, C 3-6 cycloalkyl group or 3-6 membered heterocyclic group, preferably oxo group, C 3-6 cycloalkyl group or containing 1-3 N , O or S atom 3-6 membered heterocyclic group, more preferably oxo, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxetanyl, oxetanyl, oxetanyl Pentyl, oxetanyl, azetidinyl, azetidinyl, azetidinyl or azetidinyl, more preferably oxo, cyclopropyl or oxetanyl.
- R 4 is selected from hydrogen, C 1-6 alkyl, halogen, cyano, C 1-6 haloalkyl or C 3-8 cycloalkyl, preferably hydrogen, C 1-3 alkyl, halogen, cyano, C 1 -3 haloalkyl or C 3-6 cycloalkyl, more preferably hydrogen, methyl, ethyl, propyl, fluorine, chlorine, bromine, cyano, fluoromethyl, fluoroethyl, chloromethyl, chloroethyl , Trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, more preferably hydrogen, fluorine, chlorine, methyl, trifluoromethyl Group, cyano or cyclopropyl.
- R 5 is selected from hydrogen, C 1-6 alkyl or C 1-6 haloalkyl, preferably hydrogen, C 1-3 alkyl or C 1-3 haloalkyl, more preferably hydrogen, methyl, ethyl, propyl, Fluorine-containing methyl, fluorine-containing ethyl, fluorine-containing propyl, chloromethyl, chloroethyl or chloropropyl, more preferably hydrogen or methyl;
- R 1 or R 1 ' is connected with R 5 to form a 3-6 membered heterocyclic group, optionally substituted by one or more substituents of fluorine, chlorine, bromine, methyl, ethyl or propyl, preferably nitrogen Heteropropyl, azetidinyl, azetidinyl, azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidine Cyclohexyl, methyl-substituted azetidinyl, methyl-substituted azetidinyl, methylpyrrolidinyl or methyl-substituted azetidinyl, more preferably
- R aa , R bb and R cc are each independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl or 3-8 membered heterocyclic group, preferably hydrogen, C 1-3 alkyl, C 1-3 alkoxy, C 3-6 cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, more preferably hydrogen, methyl, ethyl Group, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxetanyl, oxolanyl or Oxetanyl is more preferably hydrogen, methyl, ethyl, isopropyl, methoxy, cyclopropyl or oxetanyl.
- M is selected from sulfuric acid, phosphoric acid, benzenesulfonic acid, cinnamic acid, tartaric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, fumaric acid or methanesulfonic acid, preferably sulfuric acid, tartaric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, fumaric acid or methanesulfonic acid, more preferably sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid or methanesulfonic acid, and still more preferably ethanesulfonic acid.
- the acid addition salt represented by the general formula (I), wherein the W is O.
- the acid addition salt represented by the general formula (I), wherein the G is O or S.
- W is selected from -O-, -S- or -NR aa -;
- G is selected from -O- or -S-;
- R 1 and R 1 ' are selected from hydrogen, methyl, methoxy, isopropyl, fluoromethyl, hydroxymethyl, oxetanyl, -CH 2 OCH 3 or -CH(CH 3 )OCH 3 ;
- R 2 is selected from hydrogen, fluorine, methyl, methoxy or cyano
- R 3 and R 3 ′ are selected from hydrogen, fluorine, methyl, methoxy or cyano;
- R 4 is selected from hydrogen, fluorine, chlorine, methyl, trifluoromethyl, cyano or cyclopropyl
- R 5 is selected from hydrogen or methyl
- R aa , R bb and R cc are each independently selected from hydrogen, methyl, ethyl, isopropyl, methoxy, cyclopropyl, or oxetanyl.
- R 5 is hydrogen
- R 1 is methyl
- R 1 ' is hydrogen
- R 2 is hydrogen
- R 3 and R 3 ' are hydrogen
- R 4 When it is hydrogen, G is not -O-.
- the acid addition salt represented by the general formula (I) has a structure as shown in the formula (II-A) or (II-B):
- the acid addition salt of formula (I) is crystalline or amorphous.
- the acid addition salt represented by the general formula (I) includes crystalline and amorphous forms, wherein the acid addition salt of the formula (I) is a hydrate or Anhydrous, preferably anhydrous.
- the present invention further provides a method for preparing the acid addition salt represented by the general formula (I), which specifically includes the following steps:
- the organic solvent is selected from one or more of alcohols, esters, hydrocarbons, ketones, ethers, benzenes, amides or nitriles, preferably methanol, ethanol, isopropanol, tert-butanol , Ethyl acetate, n-hexane, heptane, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, acetone, 2-butanone, 3-pentanone, isopropyl ether, petroleum ether, methyl tert-butyl One or more of methyl ether, tetrahydrofuran, 1,4-dioxane, benzene, toluene, N,N-dimethylformamide or acetonitrile, more preferably methanol, ethanol, isopropanol, ethyl acetate , One or more of acetone, dichloromethane or aceton
- the counter ion acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, phosphoric acid, 2,5-dihydroxybenzoic acid, 1-hydroxy-2-naphthoic acid, acetic acid, dichloro Acetic acid, trichloroacetic acid, acetohydroxamic acid, adipic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, benzoic acid, 4-acetylaminobenzoic acid, 4-aminobenzoic acid, capric acid, caproic acid, caprylic acid, Cinnamic acid, citric acid, cyclohexane sulfamic acid, camphor sulfonic acid, aspartic acid, camphor acid, gluconic acid, glucuronic acid, glutamic acid, erythorbic acid, lactic acid, malic acid, mandelic acid, py
- the concentration of the organic solvent in the step 2) is 0.8-3.0 mol/L, preferably 1.0-2.5 mol/L, more preferably 1.2-2.2 mol/L.
- the vacuum temperature in the step 3) is 30-60°C, preferably 35-50°C, more preferably 40°C.
- the amount of counterion acid in step 3) is 0.4 to 2.0 equivalents, preferably 0.5 to 1.5 equivalents, and more preferably 0.6 to 1.2 equivalents.
- the present invention further provides a method for preparing the compound represented by the general formula (I) and the crystal form thereof, which specifically includes the following steps:
- step 3 Optionally, add an organic solvent to the solid obtained in step 3), stir and crystallize;
- the poor solvent is selected from one or more of alcohols, esters, ketones, ethers, benzenes, amides or nitriles, preferably methanol, ethanol, n-propanol, isopropanol, n-propanol Butanol, isobutanol, tert-butanol, ethyl acetate, acetone, 2-butanone, tetrahydrofuran, 1,4-dioxane, benzene, toluene, N,N-dimethylformamide, N,N -One or more of dimethylacetamide or acetonitrile, more preferably one or more of methanol, ethanol, isopropanol, tetrahydrofuran, ethyl acetate, acetonitrile or acetone, more preferably methanol, ethanol, isopropanol One or more of propanol, tetrahydrofuran
- the organic solvent in step 2) is selected from one or more of alcohols, esters, hydrocarbons, ketones, ethers, benzenes, amides or nitriles, preferably methanol, ethanol, isopropanol, Tert-butanol, ethyl acetate, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, n-hexane, heptane, acetone, 2-butanone, 3-pentanone, petroleum ether, tetrahydrofuran, methyl tertiary One or more of butyl ether, isopropyl ether, 1,4-dioxane, benzene, toluene, N,N-dimethylformamide or acetonitrile, more preferably methanol, ethanol, isopropanol, One or more of tert-butanol, acetone, tetrahydrofuran, to
- the counter ion acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, phosphoric acid, 2,5-dihydroxybenzoic acid, 1-hydroxy-2-naphthoic acid, acetic acid, dichloro Acetic acid, trichloroacetic acid, acetohydroxamic acid, adipic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, benzoic acid, 4-acetylaminobenzoic acid, 4-aminobenzoic acid, capric acid, caproic acid, caprylic acid, Cinnamic acid, citric acid, cyclohexane sulfamic acid, camphor sulfonic acid, aspartic acid, camphor acid, gluconic acid, glucuronic acid, glutamic acid, erythorbic acid, lactic acid, malic acid, mandelic acid, py
- the organic solvent is selected from one or more of alcohols, esters or ethers, preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, petroleum ether, methyl tert-butyl One or more of methyl ether, tetrahydrofuran or 1,4-dioxane, more preferably one of methanol, ethanol, n-propanol, isopropanol, ethyl acetate, methyl tert-butyl ether or tetrahydrofuran One or more, more preferably one or more of methanol, ethanol, isopropanol, ethyl acetate or methyl tert-butyl ether.
- alcohols, esters or ethers preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, petroleum ether, methyl tert-butyl
- the present invention further provides a method for preparing the compound represented by the general formula (I) and the crystal form thereof, which specifically includes the following steps:
- the poor solvent is selected from one or more of alcohols, ketones, esters, ethers, benzenes, amides or nitriles, preferably methanol, ethanol, n-propanol, isopropanol, n-propanol Butanol, isobutanol, tert-butanol, acetone, 2-butanone, ethyl acetate, tetrahydrofuran, 1,4-dioxane, benzene, toluene, N,N-dimethylformamide, N,N -One or more of dimethylacetamide or acetonitrile, more preferably one or more of methanol, ethanol, n-propanol, isopropanol, 88% acetone or acetonitrile.
- the suspension density in the step 1) is 20-200 mg/mL, preferably 30-150 mg/mL, more preferably 50-100 mg/mL;
- the temperature in the step 2) is 20 to 80°C, preferably 25 to 60°C, more preferably 25 to 40°C; the time is 1-15 days, preferably 1 to 10 days;
- the temperature of the vacuum drying is 20-60°C, preferably 20-50°C, more preferably 40°C.
- the present invention further provides a method for preparing the compound represented by the general formula (I) and the crystal form thereof, which specifically includes the following steps:
- the present invention further provides a method for preparing the compound represented by the general formula (I) and the crystal form thereof, which specifically includes the following steps:
- step 4) a salt of an appropriate amount of the compound
- the poor solvent is selected from one or more of alcohols, ketones, esters, ethers, benzenes, amides or acetonitrile, preferably methanol, ethanol, n-propanol, isopropanol , N-butanol, isobutanol, tert-butanol, acetone, 2-butanone, ethyl acetate, tetrahydrofuran, 1,4-dioxane, benzene, toluene, N,N-dimethylformamide, N , One or more of N-dimethylacetamide or acetonitrile, more preferably one or more of methanol, ethanol, n-propanol, isopropanol, acetone or acetonitrile;
- the counter ion acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, phosphoric acid, 2,5-dihydroxybenzoic acid, 1-hydroxy-2-naphthoic acid, acetic acid , Dichloroacetic acid, trichloroacetic acid, acetohydroxamic acid, adipic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, benzoic acid, 4-acetylaminobenzoic acid, 4-aminobenzoic acid, capric acid, caproic acid , Caprylic acid, cinnamic acid, citric acid, cyclohexane sulfamic acid, camphor sulfonic acid, aspartic acid, camphor acid, gluconic acid, glucuronic acid, glutamic acid, erythorbic acid, lactic acid, malic acid, man
- the organic solvent in step 2) is selected from alcoholic solvents, preferably one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol or tert-butanol, Preferably one or more of methanol, ethanol, isopropanol or tert-butanol;
- the heating temperature in step 3) is 30-80°C, preferably 40-60°C, more preferably 50°C;
- the organic solvent in step 4) is selected from one or more of alcohols, esters or ethers, preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, petroleum ether, One or more of methyl tert-butyl ether, tetrahydrofuran or 1,4-dioxane, more preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, methyl tert-butyl ether or One or more of tetrahydrofuran, more preferably one or more of methanol, ethanol, isopropanol, ethyl acetate or methyl tert-butyl ether.
- alcohols, esters or ethers preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, petroleum ether, One or more of methyl tert
- the present invention further provides a method for preparing the compound represented by the general formula (I) and the crystal form thereof, which specifically includes the following steps:
- step 3 Optionally, add an appropriate amount of compound salt to the solution in step 3), stir and crystallize;
- the poor solvent is selected from one or more of alcohols, ketones, esters, ethers, benzenes, amides or acetonitrile, preferably methanol, ethanol, n-propanol, isopropanol , N-butanol, isobutanol, tert-butanol, acetone, 2-butanone, ethyl acetate, tetrahydrofuran, 1,4-dioxane, benzene, toluene, N,N-dimethylformamide, N , One or more of N-dimethylacetamide or acetonitrile, more preferably one or more of methanol, ethanol, n-propanol, isopropanol, acetone or acetonitrile;
- the counter ion acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, phosphoric acid, 2,5-dihydroxybenzoic acid, 1-hydroxy-2-naphthoic acid, acetic acid , Dichloroacetic acid, trichloroacetic acid, acetohydroxamic acid, adipic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, benzoic acid, 4-acetylaminobenzoic acid, 4-aminobenzoic acid, capric acid, caproic acid , Caprylic acid, cinnamic acid, citric acid, cyclohexane sulfamic acid, camphor sulfonic acid, aspartic acid, camphor acid, gluconic acid, glucuronic acid, glutamic acid, erythorbic acid, lactic acid, malic acid, man
- the organic solvent in step 2) is selected from alcoholic solvents, preferably one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol or tert-butanol, Preferably one or more of methanol, ethanol, isopropanol or tert-butanol;
- the organic solvent in step 3) is selected from one or more of alcohols, esters or ethers, preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, petroleum ether, One or more of methyl tert-butyl ether, tetrahydrofuran or 1,4-dioxane, more preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, methyl tert-butyl ether or One or more of tetrahydrofuran, more preferably one or more of methanol, ethanol, isopropanol, ethyl acetate or methyl tert-butyl ether.
- alcohols, esters or ethers preferably methanol, ethanol, n-propanol, isopropanol, ethyl acetate, petroleum ether, One or more of methyl tert
- its X-ray powder diffraction pattern includes 2 ⁇ of 6.8 ⁇ 0.2° and 13.4 ⁇ 0.2°, 14.7 ⁇ 0.2° and 19.5 ⁇ 0.2°, 20.1 ⁇ 0.2°, 23.9 ⁇ 0.2°, 24.4 ⁇ 0.2°, 25.0 ⁇ 0.2
- its X-ray powder diffraction pattern includes two or three diffraction peaks of 2 ⁇ of 6.8 ⁇ 0.2°, 13.4 ⁇ 0.2°, 14.7 ⁇ 0.2°, and 19.5 ⁇ 0.2°, optionally further comprising 2 ⁇ of 20.1
- its X-ray powder diffraction pattern is at 13.4 ⁇ 0.2°, 14.7 ⁇ 0.2°, 19.5 ⁇ 0.2°, 20.1 ⁇ 0.2°, 23 ⁇ 0.2°, 23.9 ⁇ 0.2°, 24.4 ⁇ 0.2° and 25.0 ⁇ 0.2 Characteristic peaks;
- Its X-ray powder diffraction pattern has characteristics at 6.8 ⁇ 0.2°, 13.4 ⁇ 0.2°, 14.7 ⁇ 0.2°, 19.5 ⁇ 0.2°, 20.1 ⁇ 0.2°, 23.9 ⁇ 0.2°, 23 ⁇ 0.2° and 23.6 ⁇ 0.2° peak;
- Its X-ray powder diffraction pattern has characteristic peaks at 6.8 ⁇ 0.2°, 13.4 ⁇ 0.2°, 14.7 ⁇ 0.2°, 19.5 ⁇ 0.2°, 20.1 ⁇ 0.2°, 23.9 ⁇ 0.2°, 24.4 ⁇ 0.2° and 25.0 ⁇ 0.2 ;
- the X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 6.8 ⁇ 0.2°, 9.3 ⁇ 0.2°, 13.4 ⁇ 0.2°, and 14.7 ⁇ 0.2°; further comprising: 17.3 ⁇ 0.2° 2 ⁇ There are diffraction peaks at, 19.5 ⁇ 0.2°, 20.8 ⁇ 0.2°, 23.9 ⁇ 0.2° and 25.0 ⁇ 0.2°; further including 2 ⁇ of 9.8 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.1 ⁇ 0.2°, 20.1 ⁇ 0.2° There are diffraction peaks at, 23.0 ⁇ 0.2°, 23.6 ⁇ 0.2°, 24.4 ⁇ 0.2°, 27.3 ⁇ 0.2° and 30.7 ⁇ 0.2°; further including 2 ⁇ at 10.5 ⁇ 0.2°, 17.5 ⁇ 0.2°, 26.9 ⁇ 0.2° , 27.7 ⁇ 0.2°, 28.6 ⁇ 0.2°, 29.6 ⁇ 0.2°, 35.7 ⁇ 0.2° and 37.6 ⁇ 0.2° have diffraction peaks;
- the X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 6.8 ⁇ 0.2° and 13.4 ⁇ 0.2°; preferably, it also includes diffraction peaks at 2 ⁇ of 14.7 ⁇ 0.2° and 19.5 ⁇ 0.2°; more preferably , Also includes diffraction peaks at 2 ⁇ ( ⁇ 0.2°) of 20.1 ⁇ 0.2°, 23.9 ⁇ 0.2°, 24.4 ⁇ 0.2°, and 25.0 ⁇ 0.2°; further preferably, it also contains diffraction peaks at 23 ⁇ 0.2° and 23.6 ⁇ 0.2 ° has a diffraction peak; further preferably, it also includes diffraction peaks at 9.3 ⁇ 0.2° and 17.3 ⁇ 0.2°; even more preferably, it also contains diffraction peaks at 2 ⁇ of 9.8 ⁇ 0.2°, 18.4 ⁇ 0.2°, 19.1 ⁇ 0.2 °, 23.6 ⁇ 0.2°, 27.3 ⁇ 0.2°, and 30.7 ⁇ 0.2° have diffraction peaks; further preferably, the 2 ⁇ is 10.5 ⁇ 0.2°, 17.5 ⁇ 0.2°,
- the diffraction pattern is basically as shown in Fig. 1; the TGA pattern is basically as shown in Fig. 2; and the DSC pattern is basically as shown in Fig. 3.
- the X-ray powder diffraction pattern at 2 ⁇ is 6.1 ⁇ 0.2°, 7.5 ⁇ 0.2°, 8.0 ⁇ 0.2°, 14.9 ⁇ 0.2°, 23.8 ⁇ 0.2°, 8.4 ⁇ 0.2°, 18.8 ⁇ 0.2°, 20.7 ⁇ 0.2 °, 22.3 ⁇ 0.2°, 22.8 ⁇ 0.2°, there are diffraction peaks; preferably, there are diffraction peaks at any of 2, 4, 6, 8, or 10;
- its X-ray powder diffraction pattern contains two or three diffraction peaks among 2 ⁇ of 6.1 ⁇ 0.2°, 7.5 ⁇ 0.2° and 8.0 ⁇ 0.2°, optionally further comprising 2 ⁇ of 14.9 ⁇ 0.2°, 18.8 One or more diffraction peaks among ⁇ 0.2°, 20.7 ⁇ 0.2°, 22.3 ⁇ 0.2°, 22.8 ⁇ 0.2°, and 23.8 ⁇ 0.2°; preferably including 2, 3, 4, 5 or 6 of them ;
- its X-ray powder diffraction pattern is at 6.1 ⁇ 0.2°, 7.5 ⁇ 0.2°, 8.0 ⁇ 0.2°, 14.9 ⁇ 0.2°, 18.8 ⁇ 0.2°, 22.3 ⁇ 0.2°, 22.8 ⁇ 0.2° and 23.8 ⁇ 0.2° There are characteristic peaks.
- the X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 6.1 ⁇ 0.2°, 7.5 ⁇ 0.2°, 8.0 ⁇ 0.2°, 14.9 ⁇ 0.2°, and 23.8 ⁇ 0.2°; further including 2 ⁇ of 8.4 ⁇ 0.2°, There are diffraction peaks at 18.8 ⁇ 0.2°, 20.7 ⁇ 0.2°, 22.3 ⁇ 0.2°, and 22.8 ⁇ 0.2°; further including diffraction peaks at 2 ⁇ of 13.5 ⁇ 0.2° and 25.2 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 24.4 ⁇ 0.2°, 13.3 ⁇ 0.2°, 23.8 ⁇ 0.2°, 20.3 ⁇ 0.2°, 19.7 ⁇ 0.2°, 17.2 ⁇ 0.2°, 26.7 ⁇ 0.2°, 9.0 ⁇ 0.2
- its X-ray powder diffraction pattern has two or three diffraction peaks among 24.4 ⁇ 0.2°, 13.3 ⁇ 0.2° and 23.8 ⁇ 0.2°, optionally further including 2 ⁇ of 9.0 ⁇ 0.2°, 9.9 ⁇ 0.2°
- its X-ray powder diffraction pattern is at 24.4 ⁇ 0.2°, 13.3 ⁇ 0.2°, 23.8 ⁇ 0.2°, 9.0 ⁇ 0.2°, 9.9 ⁇ 0.2°, 26.7 ⁇ 0.2°, 17.2 ⁇ 0.2° and 23.1 ⁇ 0.2° There are characteristic peaks.
- the X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 9.0 ⁇ 0.2°, 13.3 ⁇ 0.2°, 19.7 ⁇ 0.2°, and 23.1 ⁇ 0.2°; further including 2 ⁇ of 9.9 ⁇ 0.2°, 17.2 ⁇ 0.2°, There are diffraction peaks at 20.3 ⁇ 0.2° and 26.7 ⁇ 0.2°; further include diffraction peaks at 2 ⁇ of 14.3 ⁇ 0.2°, 21.6 ⁇ 0.2°, 23.8 ⁇ 0.2°, and 28.4 ⁇ 0.2°; and further include diffraction peaks at 2 ⁇ There are diffraction peaks at 24.4 ⁇ 0.2°, 30.5 ⁇ 0.2° and 32.6 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 22.5 ⁇ 0.2°, 8.5 ⁇ 0.2°, 7.2 ⁇ 0.2°, 14.4 ⁇ 0.2°, 26.7 ⁇ 0.2°, 25.3 ⁇ 0.2°, 12.8 ⁇ 0.2°, 16.7 ⁇ 0.2
- its X-ray powder diffraction pattern has two or three diffraction peaks in 2 ⁇ of 22.5 ⁇ 0.2°, 8.5 ⁇ 0.2° and 7.2 ⁇ 0.2°, optionally further including 2 ⁇ of 14.4 ⁇ 0.2°, 26.7 ⁇ One or more diffraction peaks among 0.2°, 12.8 ⁇ 0.2°, 16.7 ⁇ 0.2° and 6.1 ⁇ 0.2°; preferably including 2, 3, 4 or 5 of them;
- its X-ray powder diffraction pattern at 2 ⁇ is 22.5 ⁇ 0.2°, 8.5 ⁇ 0.2°, 7.2 ⁇ 0.2°, 14.4 ⁇ 0.2°, 26.7 ⁇ 0.2°, 12.8 ⁇ 0.2°, 16.7 ⁇ 0.2° and 6.1 ⁇ 0.2
- a characteristic peak at ° is 22.5 ⁇ 0.2°, 8.5 ⁇ 0.2°, 7.2 ⁇ 0.2°, 14.4 ⁇ 0.2°, 26.7 ⁇ 0.2°, 12.8 ⁇ 0.2°, 16.7 ⁇ 0.2° and 6.1 ⁇ 0.2
- its X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 7.2 ⁇ 0.2°, 14.4 ⁇ 0.2°, 22.5 ⁇ 0.2° and 26.7 ⁇ 0.2°; further including 2 ⁇ of 6.1 ⁇ 0.2°, 12.8 ⁇ 0.2° There are diffraction peaks at, 16.7 ⁇ 0.2° and 20.8 ⁇ 0.2°; further included are diffraction peaks at 2 ⁇ of 8.5 ⁇ 0.2°, 15.2 ⁇ 0.2°, 22.0 ⁇ 0.2° and 25.3 ⁇ 0.2°; further included There are diffraction peaks at 2 ⁇ of 12.1 ⁇ 0.2°, 19.1 ⁇ 0.2°, and 23.8 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 8.4 ⁇ 0.2°, 7.2 ⁇ 0.2°, 20.1 ⁇ 0.2°, 22.7 ⁇ 0.2°, 24.5 ⁇ 0.2°, 25.7 ⁇ 0.2°, 18.9 ⁇ 0.2°, 26.7 ⁇ 0.2
- its X-ray powder diffraction pattern has two or three diffraction peaks in 2 ⁇ of 8.4 ⁇ 0.2°, 7.2 ⁇ 0.2° and 20.1 ⁇ 0.2°, optionally further comprising 2 ⁇ of 22.7 ⁇ 0.2°, 24.5 ⁇ One or more diffraction peaks among 0.2°, 25.7 ⁇ 0.2°, 18.9 ⁇ 0.2° and 16.4 ⁇ 0.2°; preferably including 2, 3, 4 or 5 of them;
- its X-ray powder diffraction pattern at 2 ⁇ is 8.4 ⁇ 0.2°, 7.2 ⁇ 0.2°, 20.1 ⁇ 0.2°, 22.7 ⁇ 0.2°, 24.5 ⁇ 0.2°, 25.7 ⁇ 0.2°, 18.9 ⁇ 0.2° and 16.4 ⁇ 0.2
- a diffraction peak at ° is 8.4 ⁇ 0.2°, 7.2 ⁇ 0.2°, 20.1 ⁇ 0.2°, 22.7 ⁇ 0.2°, 24.5 ⁇ 0.2°, 25.7 ⁇ 0.2°, 18.9 ⁇ 0.2° and 16.4 ⁇ 0.2
- its X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 7.2 ⁇ 0.2°, 8.4 ⁇ 0.2°, 20.1 ⁇ 0.2°, and 22.7 ⁇ 0.2°; further including 2 ⁇ of 5.8 ⁇ 0.2°, 16.4 ⁇ 0.2° There are diffraction peaks at, 18.9 ⁇ 0.2° and 26.7 ⁇ 0.2°; further include diffraction peaks at 2 ⁇ of 12.6 ⁇ 0.2°, 14.7 ⁇ 0.2°, 17.2 ⁇ 0.2°, and 25.1 ⁇ 0.2°; further included There are diffraction peaks at 2 ⁇ of 14.4 ⁇ 0.2°, 18.2 ⁇ 0.2°, 24.5 ⁇ 0.2°, and 25.7 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 4.8 ⁇ 0.2°, 7.6 ⁇ 0.2°, 12.2 ⁇ 0.2°, 14.0 ⁇ 0.2°, 18.5 ⁇ 0.2°, 22.9 ⁇ 0.2°, 23.8 ⁇ 0.2° and 24.9 ⁇ 0.2
- its X-ray powder diffraction pattern at 2 ⁇ is 4.8 ⁇ 0.2°, 7.6 ⁇ 0.2°, 12.2 ⁇ 0.2°, 14.0 ⁇ 0.2°, 18.5 ⁇ 0.2°, 22.9 ⁇ 0.2°, 23.8 ⁇ 0.2° and 24.9 ⁇ 0.2
- a diffraction peak at ° is 4.8 ⁇ 0.2°, 7.6 ⁇ 0.2°, 12.2 ⁇ 0.2°, 14.0 ⁇ 0.2°, 18.5 ⁇ 0.2°, 22.9 ⁇ 0.2°, 23.8 ⁇ 0.2° and 24.9 ⁇ 0.2
- its X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 4.8 ⁇ 0.2° and 7.6 ⁇ 0.2°; further including 2 ⁇ of 12.2 ⁇ 0.2°, 14.0 ⁇ 0.2°, 18.5 ⁇ 0.2°, 22.9 ⁇ 0.2° And there is a diffraction peak at 23.8 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 24.5 ⁇ 0.2°, 13.3 ⁇ 0.2°, 23.9 ⁇ 0.2°, 9.0 ⁇ 0.2°, 17.3 ⁇ 0.2°, 19.4 ⁇ 0.2°, 26.9 ⁇ 0.2°, 20.4 ⁇ 0.2
- its X-ray powder diffraction pattern has two or three diffraction peaks in 2 ⁇ of 24.5 ⁇ 0.2°, 13.3 ⁇ 0.2° and 23.9 ⁇ 0.2°, optionally further including 2 ⁇ of 9.0 ⁇ 0.2°, 17.3 ⁇ One or more diffraction peaks among 0.2°, 19.4 ⁇ 0.2°, 17.7 ⁇ 0.2° and 9.9 ⁇ 0.2°; preferably including 2, 3, 4 or 5 of them;
- its X-ray powder diffraction pattern at 2 ⁇ is 24.5 ⁇ 0.2°, 13.3 ⁇ 0.2°, 23.9 ⁇ 0.2°, 9.0 ⁇ 0.2°, 17.3 ⁇ 0.2°, 19.4 ⁇ 0.2°, 17.7 ⁇ 0.2° and 9.9 ⁇ 0.2
- a diffraction peak at ° is 24.5 ⁇ 0.2°, 13.3 ⁇ 0.2°, 23.9 ⁇ 0.2°, 9.0 ⁇ 0.2°, 17.3 ⁇ 0.2°, 19.4 ⁇ 0.2°, 17.7 ⁇ 0.2° and 9.9 ⁇ 0.2
- its X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 9.0 ⁇ 0.2°, 13.3 ⁇ 0.2°, 17.3 ⁇ 0.2°, and 24.5 ⁇ 0.2°; further including 2 ⁇ of 9.9 ⁇ 0.2°, 17.7 ⁇ 0.2° There are diffraction peaks at, 19.4 ⁇ 0.2° and 26.9 ⁇ 0.2°; further include diffraction peaks at 2 ⁇ of 14.3 ⁇ 0.2°, 18.6 ⁇ 0.2°, 28.3 ⁇ 0.2°, and 37.5 ⁇ 0.2°; further contained in There are diffraction peaks at 2 ⁇ of 16.7 ⁇ 0.2°, 20.0 ⁇ 0.2°, 20.4 ⁇ 0.2°, 24.0 ⁇ 0.2°, and 30.4 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 7.6 ⁇ 0.2°, 22.5 ⁇ 0.2°, 8.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 23.9 ⁇ 0.2°, 26.6 ⁇ 0.2°, 24.6 ⁇ 0.2°, 5.8 ⁇ 0.2
- its X-ray powder diffraction pattern has two or three diffraction peaks in 2 ⁇ of 7.6 ⁇ 0.2°, 22.5 ⁇ 0.2° and 8.9 ⁇ 0.2°, optionally further including 2 ⁇ of 15.0 ⁇ 0.2°, 26.6 ⁇ One or more diffraction peaks among 0.2°, 5.8 ⁇ 0.2°, 12.9 ⁇ 0.2° and 11.6 ⁇ 0.2°; preferably including 2, 3, 4 or 5 of them;
- its X-ray powder diffraction pattern at 2 ⁇ is 7.6 ⁇ 0.2°, 22.5 ⁇ 0.2°, 8.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 26.6 ⁇ 0.2°, 5.8 ⁇ 0.2°, 12.9 ⁇ 0.2° and 11.6 ⁇ 0.2
- a diffraction peak at ° is 7.6 ⁇ 0.2°, 22.5 ⁇ 0.2°, 8.9 ⁇ 0.2°, 15.0 ⁇ 0.2°, 26.6 ⁇ 0.2°, 5.8 ⁇ 0.2°, 12.9 ⁇ 0.2° and 11.6 ⁇ 0.2
- its X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 7.6 ⁇ 0.2°, 15.0 ⁇ 0.2°, 22.5 ⁇ 0.2°, and 23.9 ⁇ 0.2°; further including 2 ⁇ of 5.8 ⁇ 0.2°, 12.9 ⁇ 0.2° There are diffraction peaks at, 19.9 ⁇ 0.2° and 26.6 ⁇ 0.2°; further include diffraction peaks at 2 ⁇ of 8.9 ⁇ 0.2°, 16.8 ⁇ 0.2°, 20.7 ⁇ 0.2° and 24.6 ⁇ 0.2°; further contained in 2 ⁇ There are diffraction peaks at 10.1 ⁇ 0.2°, 11.6 ⁇ 0.2°, 17.4 ⁇ 0.2°, 18.2 ⁇ 0.2°, 19.1 ⁇ 0.2°, 21.9 ⁇ 0.2°, 25.4 ⁇ 0.2° and 27.7 ⁇ 0.2°.
- the X-ray powder diffraction pattern at 2 ⁇ is 17.7 ⁇ 0.2°, 23.5 ⁇ 0.2°, 24.8 ⁇ 0.2°, 9.9 ⁇ 0.2°, 22.6 ⁇ 0.2°, 21.2 ⁇ 0.2°, 19.1 ⁇ 0.2°, 29.4 ⁇ 0.2
- its X-ray powder diffraction pattern has two or three diffraction peaks in 2 ⁇ of 17.7 ⁇ 0.2°, 23.5 ⁇ 0.2° and 24.8 ⁇ 0.2°, optionally further including 2 ⁇ of 9.9 ⁇ 0.2°, 22.6 ⁇
- its X-ray powder diffraction pattern at 2 ⁇ is 17.7 ⁇ 0.2°, 23.5 ⁇ 0.2°, 24.8 ⁇ 0.2°, 9.9 ⁇ 0.2°, 22.6 ⁇ 0.2°, 21.2 ⁇ 0.2°, 19.1 ⁇ 0.2° and 29.4 ⁇ 0.2
- a diffraction peak at ° is 17.7 ⁇ 0.2°, 23.5 ⁇ 0.2°, 24.8 ⁇ 0.2°, 9.9 ⁇ 0.2°, 22.6 ⁇ 0.2°, 21.2 ⁇ 0.2°, 19.1 ⁇ 0.2° and 29.4 ⁇ 0.2
- its X-ray powder diffraction pattern has diffraction peaks at 2 ⁇ of 9.9 ⁇ 0.2°, 17.7 ⁇ 0.2°, 22.6 ⁇ 0.2°, and 24.8 ⁇ 0.2°; further including 2 ⁇ at 16.9 ⁇ 0.2°, 21.2 ⁇ 0.2°
- diffraction peaks at, 23.5 ⁇ 0.2° and 29.4 ⁇ 0.2° further include diffraction peaks at 2 ⁇ of 17.3 ⁇ 0.2°, 19.1 ⁇ 0.2°, 28.4 ⁇ 0.2°, and 30.5 ⁇ 0.2°; further contained in There are diffraction peaks at 2 ⁇ of 14.1 ⁇ 0.2°, 16.2 ⁇ 0.2°, 19.6 ⁇ 0.2°, 20.7 ⁇ 0.2°, 24.5 ⁇ 0.2°, and 26.5 ⁇ 0.2°.
- the object of the present invention is also to provide a pharmaceutical composition, which contains a therapeutically effective amount of the compound represented by formula (I) and its crystal form, and one or more pharmaceutically acceptable carriers, diluents or excipient,
- W is selected from -O-, -S- or -NR aa -;
- G is selected from -O-, -S-, -CR aa R bb -or -NR aa -;
- R 1 and R 1 ' are selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkane Group, cyano substituted C 1-6 alkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl, 5-10 membered heteroaryl, -(CH 2 ) n R cc , -(CH 2 ) n OR cc or -CR aa R bb OR cc ;
- R 1 and R 1 ' are connected to form a C 3-8 cycloalkyl group or a 3-8 membered heterocyclic group, wherein the C 3-8 cycloalkyl group or a 3-8 membered heterocyclic group is optionally further Deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl , 3-8 membered heterocyclic group, C 6-10 aryl group and 5-10 membered heteroaryl group substituted by one or more substituents;
- R 2 is selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3 -8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, 5-10 membered heteroaryl or -(CH 2 ) n OR cc ;
- R 3 and R 3 ' are selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkane Group, C 3-8 cycloalkyl group, 3-8 membered heterocyclic group, C 6-10 aryl group or 5-10 membered heteroaryl group;
- R 3 and R 3' are connected to form an oxo group, a C 3-8 cycloalkyl group or a 3-8 membered heterocyclic group, wherein the C 3-8 cycloalkyl group or a 3-8 membered heterocyclic group ,
- R 4 is selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3 -8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
- R 5 is selected from hydrogen, deuterium, C 1-6 alkyl or C 1-6 haloalkyl
- R 1 or R 1 ′ and R 5 are connected to form a 3-8 membered heterocyclic group, wherein the 3-8 membered heterocyclic group is optionally further substituted by deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 One or more substituents in the aryl group and 5-10 membered heteroaryl group;
- R aa , R bb and R cc are each independently selected from hydrogen, deuterium, cyano, halogen, nitro, amino, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl;
- M is an inorganic acid or an organic acid, wherein the inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid or phosphoric acid; the organic acid is selected from 2,5-dihydroxybenzoic acid, 1- Hydroxy-2-naphthoic acid, acetic acid, dichloroacetic acid, trichloroacetic acid, acetohydroxamic acid, adipic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, benzoic acid, 4-acetylaminobenzoic acid, 4-amino Benzoic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclohexane sulfamic acid, camphor sulfonic acid, aspartic acid, camphor acid, gluconic acid, glucuronic acid, glutamic acid,
- n is an integer from 0 to 3;
- x is an integer from 0 to 3;
- y is an integer of 1-5, preferably an integer of 1-3, and more preferably 1.
- R 1 and R 1 ' are selected from hydrogen, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, 3-8 membered heterocyclyl, -( CH 2 ) n OR cc or -CR aa R bb OR cc , preferably hydrogen, C 1-3 alkyl, C 1-3 hydroxyalkyl, C 1-3 haloalkyl, C 1-3 alkoxy, 3- 6-membered heterocyclic group, -(CH 2 ) n OR cc or -CR aa R bb OR cc , more preferably hydrogen, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy Group, fluoromethyl, fluoroethyl, fluoropropyl, chloromethyl, chloroethyl, chloropropyl, hydroxymethyl, hydroxyethyl, hydroxypropyl,
- R 2 is selected from hydrogen, C 1-6 alkyl, halogen, cyano or -(CH 2 ) n OR cc , preferably hydrogen, C 1-3 alkyl, halogen, cyano or -(CH 2 ) n OR cc , More preferably hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, fluorine, chlorine, bromine or cyano, further preferably hydrogen, fluorine, methyl, methoxy or cyano ;
- any two connected R 2 form a substituted or unsubstituted C 3-6 cycloalkyl group or a substituted or unsubstituted 3-6 membered heterocyclic group, preferably a substituted or unsubstituted C 3-6 cycloalkyl group Or substituted or unsubstituted 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxecyclopropyl , Oxetanyl, oxolanyl, oxanyl, azetidinyl, azetidinyl, azetidinyl, azetidinyl, more preferably cyclobutyl, cyclopentyl , 1,3-Dioxopentyl or 1,3-dioxyl.
- R 3 and R 3 ' are selected from hydrogen, C 1-6 alkyl, halogen, cyano or C 1-6 alkoxy, preferably hydrogen, C 1-3 alkyl, halogen, cyano or C 1-3 alkane Oxy group, more preferably hydrogen, methyl, ethyl, propyl, fluorine, chlorine, bromine, cyano, methoxy, ethoxy or propoxy, further preferably hydrogen, fluorine, methyl, methoxy or Cyano
- R 3 and R 3 ' are connected to form an oxo group, C 3-6 cycloalkyl group or 3-6 membered heterocyclic group, preferably oxo group, C 3-6 cycloalkyl group or containing 1-3 N , O or S atom 3-6 membered heterocyclic group, more preferably oxo, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxetanyl, oxetanyl, oxetanyl Pentyl, oxetanyl, azetidinyl, azetidinyl, azetidinyl or azetidinyl, more preferably oxo, cyclopropyl or oxetanyl.
- R 4 is selected from hydrogen, C 1-6 alkyl, halogen, cyano, C 1-6 haloalkyl or C 3-8 cycloalkyl, preferably hydrogen, C 1-3 alkyl, halogen, cyano, C 1 -3 haloalkyl or C 3-6 cycloalkyl, more preferably hydrogen, methyl, ethyl, propyl, fluorine, chlorine, bromine, cyano, fluoromethyl, fluoroethyl, chloromethyl, chloroethyl , Trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, more preferably hydrogen, fluorine, chlorine, methyl, trifluoromethyl Group, cyano or cyclopropyl.
- R 5 is selected from hydrogen, C 1-6 alkyl or C 1-6 haloalkyl, preferably hydrogen, C 1-3 alkyl or C 1-3 haloalkyl, more preferably hydrogen, methyl, ethyl, propyl, Fluorine-containing methyl, fluorine-containing ethyl, fluorine-containing propyl, chloromethyl, chloroethyl or chloropropyl, more preferably hydrogen or methyl;
- R 1 or R 1 ' is connected with R 5 to form a 3-6 membered heterocyclic group, optionally substituted by one or more substituents of fluorine, chlorine, bromine, methyl, ethyl or propyl, preferably aza Cyclopropyl, azetidinyl, azetidinyl, azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidinyl, fluorine-substituted azetidinyl Hexyl, methyl-substituted azetidinyl, methyl-substituted azetidinyl, methylpyrrolidinyl or methyl-substituted azetidinyl, more preferably azetidinyl, azetidinyl,
- R aa , R bb and R cc are each independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl or 3-8 membered heterocyclic group, preferably hydrogen, C 1-3 alkyl, C 1-3 alkoxy, C 3-6 cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, more preferably hydrogen, methyl, ethyl Group, propyl, methoxy, ethoxy, propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxetanyl, oxolanyl or Oxetanyl is more preferably hydrogen, methyl, ethyl, isopropyl, methoxy, cyclopropyl or oxetanyl.
- M is selected from sulfuric acid, phosphoric acid, benzenesulfonic acid, cinnamic acid, tartaric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, fumaric acid or methanesulfonic acid, preferably sulfuric acid, tartaric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, fumaric acid or methanesulfonic acid, more preferably sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid or methanesulfonic acid, and still more preferably ethanesulfonic acid.
- the acid addition salt represented by the general formula (I), wherein: W is -O-.
- the acid addition salt represented by the general formula (I), wherein: G is -O- or -S-.
- the acid addition salt represented by the general formula (I) is further represented by the formula (II-A) or (II-B):
- the purpose of the present invention is also to provide the application of the compound represented by formula (I) and its crystal form and the pharmaceutical composition in the preparation of PI3K inhibitor drugs, preferably in the preparation of PI3K ⁇ inhibitor drugs.
- the object of the present invention is also to provide the compound (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3- Yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propionamide salt and its crystal form, and one One or more pharmaceutically acceptable carriers, diluents or excipients.
- the object of the present invention is also to provide the compound (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3- Yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propionamide salt and its crystal form, and medicine
- the application of the composition in the preparation of PI3K inhibitor drugs, preferably in the preparation of PI3K ⁇ inhibitor drugs.
- the application is an application in the preparation of drugs for the treatment of cancer, bone disease, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease and heart disease, wherein the cancer is selected from breast cancer, pancreas Cancer, non-small cell lung cancer (NSCLC), thyroid cancer, seminoma, melanoma, bladder cancer, liver cancer, kidney cancer, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and colorectal cancer Cancer.
- NSCLC non-small cell lung cancer
- MDS myelodysplastic syndrome
- AML acute myeloid leukemia
- Figure 1 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide ethane sulfonate crystal form A XRPD diagram.
- Figure 2 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide ethane sulfonate crystal form A TGA diagram.
- Figure 3 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide ethane sulfonate form A DSC chart.
- Figure 4 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole XRPD diagram of the mesylate form A of and [1,2-d][1,4]oxazepin-9-yl)amino)propionamide.
- Figure 5 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole XRPD diagram of the mesylate form B of and [1,2-d][1,4]oxazepin-9-yl)amino)propionamide.
- Figure 6 is (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole XRPD diagram of the mesylate form C of and [1,2-d][1,4]oxazepin-9-yl)amino)propionamide.
- Figure 7 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide sulfate form A XRPD diagram.
- Figure 8 shows (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide sulfate form B XRPD diagram.
- Figure 9 is (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide sulfate form C XRPD diagram.
- Figure 10 is (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide sulfate form D XRPD diagram.
- Figure 11 is (S)-2-((2-((R)-4-(difluoromethyl)-2-carbonylthiazolidine-3-yl)-5,6-dihydrobenzo[f]imidazole And [1,2-d][1,4]oxazepin-9-yl)amino)propionamide sulfate form E XRPD diagram.
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms
- the alkyl group is most preferably an alkyl group of 1 to 3 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
- Alkyl groups may be substituted or unsubstituted. When substituted, substituents may be substituted at any available attachment point.
- the substituents are preferably one or more of the following groups, which are independently selected from alkanes Group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy or carboxylic acid ester group, preferably methyl, ethyl, isopropyl, tert-butyl, haloalkyl in the present invention , Deuterated alkyl, alkoxy-substituted alkyl, hydroxy-substituted alkyl and cyano-substi
- alkylene means that one hydrogen atom of an alkyl group is further substituted, for example: "methylene” means -CH 2 -, "ethylene” means -(CH 2 ) 2 -, “propylene” It refers to -(CH 2 ) 3 -, “butylene” refers to -(CH 2 ) 4 -, etc.
- the above substituents can be connected to different carbon atoms to form a carbon chain, or they can be connected to a carbon atom to form a cycloalkyl group.
- alkenyl refers to an alkyl group as defined above composed of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3 -Butenyl etc. Alkenyl groups may be substituted or unsubstituted.
- the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
- the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 8 carbon atoms, more preferably 3 to 6 Carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- Polycyclic cycloalkyls include spiro, fused and bridged cycloalkyls, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, which contains 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (wherein m is an integer of 0 to 2) heteroatoms, but does not include the ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably contains 3 to 8 ring atoms; most preferably contains 3 to 8 ring atoms.
- Non-limiting examples of monocyclic heterocyclic groups include oxetanyl, pyrrolidinyl, pyrrolidone, imidazolidinyl, tetrahydrofuryl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrrolidinyl Azolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably oxetanyl, pyrrolidonyl, tetrahydrofuranyl, Pyrazolidinyl, morpholinyl, piperazinyl and pyranyl.
- Polycyclic heterocyclic groups include spiro, condensed and bridged heterocyclic groups; the spiro, condensed and bridged heterocyclic groups are optionally connected to other groups through a single bond, or through a ring Any two or more of the above atoms are further connected to other cycloalkyl groups, heterocyclic groups, aryl groups and heteroaryl groups.
- alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where the definition of alkyl is as described above.
- An alkoxy group having 1 to 8 carbon atoms is preferred, an alkoxy group having 1 to 6 carbon atoms is more preferred, and an alkoxy group having 1 to 3 carbon atoms is most preferred.
- Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- the alkoxy group may be optionally substituted or unsubstituted.
- the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
- groups are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxy
- Haloalkyl refers to an alkyl group substituted with one or more halogens, wherein the alkyl group is as defined above.
- Haloalkoxy refers to an alkoxy group substituted with one or more halogens, where alkoxy is as defined above.
- Hydroalkyl refers to an alkyl group substituted with a hydroxy group, where the alkyl group is as defined above.
- Halogen refers to fluorine, chlorine, bromine or iodine.
- Amino refers to -NH 2 .
- Cyano refers to -CN.
- Niro refers to -NO 2 .
- THF tetrahydrofuran
- EtOAc refers to ethyl acetate
- DMSO dimethyl sulfoxide
- LDA lithium diisopropylamide
- DMAP refers to 4-dimethylaminopyridine.
- EtMgBr refers to ethyl magnesium bromide
- HSu refers to N-hydroxysuccinimide
- EDCl refers to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
- IPA refers to isopropanol.
- MeOH means methanol
- DMF N, N-dimethylformamide
- DIPEA N,N-diisopropylethylamine
- HEPES 4-hydroxyethylpiperazine ethanesulfonic acid
- X is selected from A, B, or C
- X is selected from A, B and C
- X is A, B or C
- X is A, B and C
- other terms all express the same Meaning, which means that X can be any one or more of A, B, and C.
- Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of each other, substituted with a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group having free hydrogen may be unstable when combined with a carbon atom having an unsaturated (eg, olefinic) bond.
- Stepoisomerism includes geometric isomerism (cis-trans isomerism), optical isomerism, and conformational isomerism.
- the hydrogen atoms described in the present invention can be replaced by its isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers And excipients.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredient and thus the biological activity.
- “Pharmaceutically acceptable salt” refers to the salt of the compound of the present invention, which is safe and effective when used in mammals, and has due biological activity.
- the new crystal form can be identified by powder X-ray diffraction spectroscopy.
- the peak intensity and/or peak condition of powder X-ray diffraction may be different due to different experimental conditions, such as different diffraction test conditions and/or preferred orientations.
- the measured 2 ⁇ value may have an error of about ⁇ 0.2, and individual peaks may have an error of about ⁇ 0.3 or ⁇ 0.4.
- the relative intensity value of the peak is more dependent on certain properties of the measured sample than the position of the peak, such as the size of the crystals in the sample, the orientation of the crystals and the purity of the material being analyzed, so the peaks displayed Intensity deviations in the range of about ⁇ 20% or more are possible.
- TGA thermogravimetric analysis
- DSC differential scanning calorimetry
- XRPD refers to X-ray powder diffraction (XRPD) experiments.
- HPLC refers to high performance liquid chromatography (HPLC) experiments.
- PK refers to pharmacokinetic (PK) experiments.
- the structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or/and liquid mass spectrometry (LC-MS).
- NMR chemical shift ( ⁇ ) is given in units of parts per million (ppm).
- the NMR was measured with Bruker AVANCE-400 nuclear magnetic instrument, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ), and the internal standard was four Methylsilane (TMS).
- the liquid mass spectrometry LC-MS measurement uses an Agilent 1200 Infinity Series mass spectrometer.
- HPLC determination uses Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150 ⁇ 4.6mm chromatographic column) and Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150 ⁇ 4.6mm chromatographic column).
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
- the specifications used for TLC are 0.15mm ⁇ 0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm ⁇ 0.5mm.
- Column chromatography generally uses 200-300 mesh Yantai Huanghai silica gel as the carrier.
- the starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized according to methods known in the art.
- the third step Preparation of 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
- Step 1 Preparation of 9-bromo-3-fluoro-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
- reaction solution was quenched with saturated aqueous ammonium chloride solution, extracted with dichloromethane (100mL ⁇ 2), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and column chromatography to obtain the title compound 9-bromo-3-fluoro -2-Iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (150mg, 29%).
- the third step Preparation of 9-bromo-2-iodo-3-methyl-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
- the first step the preparation of 1-(bicyclo[4.2.0]oct-1(6),2,4-trien-3-yl)ethane-1-one
- the fourth step preparation of 5-bromobicyclo[4.2.0]oct-1(6),2,4-trien-3-ol
- 5-bromobicyclo[4.2.0]octyl-1(6),2,4-trien-3-yl acetate 723mg, 3mmol was dissolved in methanol (20mL), and 5N sodium hydroxide aqueous solution was added (3mL), react at room temperature overnight. Add water 50mL, 1N hydrochloric acid to adjust the pH of the reaction solution to 5, extract with DCM (50mL ⁇ 2), combine the organic phases and concentrate under reduced pressure, and then column chromatography to obtain the title compound 5-bromobicyclo[4.2.0]oct-1(6) , 2,4-Trien-3-ol (567 mg, 95%).
- Methyl L-threonine ester hydrochloride (500mg, 2.95mmol) was dissolved in dichloromethane (15mL), cooled to 0°C in an ice water bath, triphosgene (289mg, 0.97mmol) was added, and triethylamine ( 895mg, 8.84mmol) in dichloromethane (2mL), after dripping, react at 0°C for 1 hour, add water, extract with dichloromethane, dry the organic phase with anhydrous sodium sulfate, concentrate the organic solvent under reduced pressure, and then the crude product column Purification by chromatography gave the title compound methyl(4S,5R)-5-methyl-2-carbonyloxazolidine-4-carboxylate (251 mg, 53%).
- Step 2 Preparation of methyl(4S,5R)-3-benzyl-5-methyl-2-carbonyloxazolidine-4-carboxylate
- Methyl (4S, 5R)-5-methyl-2-carbonyloxazolidine-4-carboxylate (200mg, 1.26mmol) was dissolved in DMF (5mL), cooled to -15°C, and NaH (60% In kerosene, 50mg, 1.26mmol), and stirred at this temperature for one hour, add benzyl bromide (322mg, 1.89mmol), continue to stir for 2 hours, add water to quench the reaction, extract with dichloromethane, the organic phase Drying with sodium sulfate, concentrating the organic solvent under reduced pressure, and purifying the crude product by column chromatography to obtain the title compound methyl(4S,5R)-3-benzyl-5-methyl-2-carbonyloxazolidine-4-carboxylate (260mg, 83%).
- the first step preparation of 4-bromo-3-fluoro-2-methoxybenzaldehyde
- the fifth step 9-bromo-8-fluoro-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine preparation
- Step 6 Preparation of 9-bromo-8-fluoro-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
- the first step preparation of 4-bromo-3-fluoro-2-methoxybenzaldehyde
- the fifth step 9-bromo-8-fluoro-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine preparation
- Step 6 Preparation of 9-bromo-8-fluoro-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
- the third step Preparation of 9-bromo-2,3-diiodo-6,7-dihydro-5H-benzo[f]imidazo[1,2-d][1,4]diazepine
- 5-bromo-2-fluorobenzaldehyde (5.0g, 24.6mmol) was dissolved in isopropanol/water (25mL/25mL), ammonium acetate (17.6g, 221.7mmol) was added, and glyoxal ( 4.5mL, 221.7mmol), stirred overnight. Dilute with isopropanol, filter the reaction solution and concentrate under reduced pressure. The concentrated solution is mixed with dichloromethane and water.
- the third step Preparation of 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]thiazepine
- test example The purpose of this test example is to test the inhibitory activity of the compounds of the examples on PI3K ⁇ / ⁇ / ⁇ / ⁇ kinase activity.
- the pipette was purchased from Eppendorf or Rainin
- microplate reader was purchased from BioTek, USA.
- Model is SynergyH1 full-function microplate reader
- This experiment uses Promega's ADP-Glo lipid kinase assay method (Promega#V9102). Lipid kinase PI3K ⁇ / ⁇ / ⁇ / ⁇ undergoes a catalytic reaction in the presence of the substrate PIP2: 3PS and ATP, and ATP generates ADP. characterized by the activity of lipid kinases and ADP content in the reaction was measured, and the obtained half maximal inhibitory concentration IC 50 for the compound PI3K ⁇ / ⁇ / ⁇ / ⁇ kinase activity inhibition.
- Enzyme name Item No. Enzyme reaction concentration Enzyme reaction time ATP concentration PI3K ⁇ Promega#V1721 0.1nM 120min 50 ⁇ M PI3K ⁇ Carna#11-102 0.4nM 90min 100 ⁇ M PI3K ⁇ Thermofisher#PV4786 0.4nM 120min 50 ⁇ M PI3K ⁇ Carna#11-103 0.1nM 90min 100 ⁇ M
- the example compounds of the present invention have good activity and selectivity in terms of PI3K ⁇ / ⁇ / ⁇ / ⁇ kinase activity.
- test example is to test the proliferation inhibitory activity of the compounds of the examples on PI3K ⁇ mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K).
- the carbon dioxide incubator was purchased from Thermo Company
- the biological safety cabinet was purchased from Shanghai Boxun Company
- the pipette was purchased from Eppendorf or Rainin
- microplate reader was purchased from BioTek, USA.
- Model is SynergyH1 full-function microplate reader
- the Cell Titer-Glo method was used to detect the proliferation inhibitory effects of the compounds of the examples on PI3K ⁇ mutant cancer cell lines (HCC1954, HGC-27 and MKN1.
- the cell lines were cultured with 10% FBS (Gibco#10091148) and 1% P/ S (Hyclone#SV30010) in the RPMI 1640 medium (Gibco#22400089), cultured at 37°C, 5% CO 2.
- Collect the cells before the experiment adjust the cell density after the cell count, and divide the cells to 1000-10000 cells /Well density is planted in a white 96-well plate (Corning#3610), placed in a 37°C, 5% CO 2 incubator overnight, then add the prepared compound solutions of different concentrations, and set the corresponding solvent control at the same time, continue to put After culturing in a 37°C, 5% CO 2 incubator for 48-96 hours, equilibrate the cell plate and its contents to room temperature, add 20-100 ⁇ L Cell Titer-Glo solution (Promega#G7573) to each well, shake and mix well and avoid at room temperature. Light incubate for 5-30 minutes, and detect the chemiluminescence value with BioTek's SynergyH1 microplate reader.
- the compound of the embodiment shown in the present invention shows the biological activity of the following table 8 in the activity test of the proliferation inhibition of PI3K ⁇ mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K) .
- the compound of the examples of the present invention has good activity on the proliferation inhibitory activity of PI3K ⁇ mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K).
Abstract
Description
酶名称 | 货号 | 酶反应浓度 | 酶反应时间 | ATP浓度 |
PI3Kα | Promega#V1721 | 0.1nM | 120min | 50μM |
PI3Kβ | Carna#11-102 | 0.4nM | 90min | 100μM |
PI3Kγ | Thermofisher#PV4786 | 0.4nM | 120min | 50μM |
PI3Kδ | Carna#11-103 | 0.1nM | 90min | 100μM |
分组 | 动物数量(只) | 给药天数(天) | 抑瘤率 |
空白对照 | 5 | 21 | - |
实施例22 | 5 | 19 | 132% |
实施例25 | 5 | 21 | 120% |
实施例50 | 5 | 21 | 96% |
实施例52 | 5 | 21 | 98% |
实施例56 | 5 | 21 | 122% |
实施例62 | 5 | 21 | 147% |
名称 | 型号 | 来源 |
分析天平 | BSA224S-CW | Sartorius |
超声波清洗仪 | SK5200LHC | 上海科导超声仪器 |
移液枪 | Eppendorf(50mL,1000μL) | Eppendorf |
编号 | 酸 | 加酸后现象 | 结果 |
1 | 1M盐酸乙醇 | 浑浊成油贴壁 | 未析出固体 |
2 | 1M硫酸乙醇 | 浑浊成油贴壁 | 未析出固体 |
3 | 1M甲磺酸乙醇 | 析出沉淀 | 得到甲磺酸盐 |
4 | 1M对苯甲磺酸乙醇 | 仍澄清 | 挥干溶剂得到油 |
5 | 1M苯磺酸乙醇 | 仍澄清 | 挥干溶剂得到油 |
6 | 1M磷酸乙醇 | 仍澄清 | 挥干溶剂得到油 |
7 | 1M草酸乙醇 | 仍澄清 | 挥干溶剂得到油 |
8 | 1M马来酸乙醇 | 仍澄清 | 挥干溶剂得到油 |
编号 | 酸 | 加酸后现象 | 结果 |
1 | 1M盐酸乙醇 | 变澄清 | 搅拌未析出固体,挥干溶剂后成油 |
2 | 1M硫酸乙醇 | 变澄清 | 搅拌未析出固体,挥干溶剂后成油 |
3 | 1M甲磺酸乙醇 | 变粘稠 | 得到甲磺酸盐 |
4 | 1M对苯甲磺酸乙醇 | 变澄清 | 搅拌未析出固体,挥干溶剂后成油 |
5 | 1M苯磺酸乙醇 | 变澄清 | 搅拌未析出固体,挥干溶剂后成油 |
6 | 1M磷酸乙醇 | 无明显现象仍混悬 | 未发生反应,仍为游离碱 |
7 | 1M草酸乙醇 | 无明显现象仍混悬 | 未发生反应,仍为游离碱 |
8 | 1M马来酸甲醇 | 无明显现象仍混悬 | 未发生反应,仍为游离碱 |
编号 | 酸 | 加酸后现象 | 后处理 |
1 | 1M盐酸乙醇 | 澄清 | 长时间搅拌均无固体析出 |
2 | 1M草酸乙醇 | 混悬 | 未反应,为游离碱晶型B |
3 | 1M HBr乙醇 | 澄清 | 长时间搅拌均无固体析出 |
4 | 1M对苯甲磺酸甲醇 | 澄清 | 长时间搅拌均无固体析出 |
5 | 0.25M 1,5奈二磺酸乙醇 | 澄清 | 长时间搅拌均无固体析出 |
6 | 1M苯磺酸甲醇 | 澄清 | 长时间搅拌均无固体析出 |
7 | 1M羟乙基磺酸甲醇 | 澄清 | 搅拌微混油状 |
8 | 1M乙烷磺酸甲醇 | 澄清 | 搅拌10min后析出固体,得到乙烷磺酸盐 |
编号 | 酸 | 加酸后现象 | 后处理 |
1 | 1M盐酸乙醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
2 | 1M草酸乙醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
3 | 1M HBr乙醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
4 | 1M对苯甲磺酸甲醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
5 | 0.25M 1,5奈二磺酸乙醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
6 | 1M苯磺酸甲醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
7 | 1M羟乙基磺酸甲醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
8 | 1M乙烷磺酸甲醇 | 仍澄清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
编号 | 酸 | 加酸后现象 | 后处理 |
1 | 1M盐酸乙醇 | 溶清 | 加入MTBE反溶剂成油,搅拌无固体析出 |
2 | 1M硫酸乙醇 | 溶清 | 加入MTBE反溶剂成油,搅拌固体析出,得到硫酸盐 |
3 | 1M马来酸甲醇 | 仍混悬 | 未反应,为游离碱 |
4 | 1M磷酸乙醇 | 仍混悬 | 未反应,为游离碱 |
5 | 1M草酸乙醇 | 仍混悬 | 未反应,为游离碱 |
编号 | 酸 | 加酸后现象 | 后处理 | 实验结果 |
1 | 马来酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
2 | 草酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
3 | 磷酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
4 | 酒石酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
5 | 富马酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
6 | 柠檬酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
7 | 乙醇酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
8 | 丁二酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
9 | 己二酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
10 | 苹果酸 | 仍澄清 | 室温挥干溶剂 | 成油 |
11 | 对苯甲磺酸 | 加酸后溶清 | 室温挥干溶剂 | 无定型 |
12 | 盐酸 | 加酸后溶清 | 室温挥干溶剂 | 无定型 |
13 | 苯磺酸 | 加酸后溶清 | 室温挥干溶剂 | 无定型 |
14 | 羟乙基磺酸 | 加酸后溶清 | 室温挥干溶剂 | 无定型 |
仪器名称 | 型号 |
分析天平 | Sartorius BSA224S-CW |
纯水机 | Milli-Q Plus,Millipore |
高效液相色谱仪 | Agilent1260 |
泵 | Agilent G1311B |
进样器 | G1329B |
柱温箱 | G1316A |
检测器 | G1315D |
超声波清洗仪 | SK5200LHC |
移液枪 | Eppendorf(50mL,1000μL) |
T(min) | A(%) | B(%) |
0.00 | 90 | 10 |
8.00 | 10 | 90 |
10.00 | 10 | 90 |
10.10 | 90 | 10 |
12.00 | 90 | 10 |
样品名称 | 乙烷磺酸盐晶型A |
介质 | 溶解度(mg/mL) |
pH1 | 9.37 |
pH2 | 0.974 |
pH3 | 0.268 |
pH4 | 0.049 |
pH5 | 0.020 |
pH6 | 0.005 |
pH7 | 0.012 |
pH8 | 0.014 |
Fa | 0.044 |
Fe | 0.163 |
SGF | 1.151 |
water | 0.608 |
Claims (29)
- 一种通式(I)所示的酸加成盐,其结构如下:其中:W选自-O-、-S-或-NR aa-;G选自-O-、-S-、-CR aaR bb-或-NR aa-;R 1和R 1’选自氢、氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、氰基取代的C 1-6烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基、5-10元杂芳基、-(CH 2) nR cc、-(CH 2) nOR cc或-CR aaR bbOR cc;或,R 1和R 1’相连形成一个C 3-8环烷基或3-8元杂环基,其中所述的C 3-8环烷基或3-8元杂环基,任选进一步被氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-10元杂芳基中的一个或多个取代基取代;R 2选自氢、氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基、5-10元杂芳基或-(CH 2) nOR cc;或,任意两个相连的R 2形成一个C 3-8环烷基或3-8元杂环基,其中所述的C 3-8环烷基或3-8元杂环基,任选进一步被氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-10元杂芳基中的一个或多个取代基取代;R 3和R 3’选自氢、氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-10元杂芳基;或,R 3和R 3’相连形成一个氧代基、C 3-8环烷基或3-8元杂环基,其中所述的C 3-8环烷基或3-8元杂环基,任选进一步被氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-10元杂芳基中的一个或多个取代基取代;R 4选自氢、氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6 烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-10元杂芳基;R 5选自氢、氘、C 1-6烷基或C 1-6卤代烷基;或,R 1或R 1’与R 5相连形成一个3-8元杂环基,其中所述的3-8元杂环基,任选进一步被氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基和5-10元杂芳基中的一个或多个取代基取代;R aa、R bb和R cc各自独立地选自氢、氘、氰基、卤素、硝基、氨基、C 1-6烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6羟烷基、C 3-8环烷基、3-8元杂环基、C 6-10芳基或5-10元杂芳基;M为无机酸或有机酸,其中所述无机酸选自盐酸、硫酸、硝酸、氢溴酸、氢氟酸、氢碘酸或磷酸;有机酸选自2,5-二羟基苯甲酸、1-羟基-2-萘甲酸、醋酸、二氯醋酸、三氯醋酸、乙酰氧肟酸、己二酸、苯磺酸、4-氯苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、4-氨基苯甲酸、癸酸、己酸、辛酸、肉桂酸、柠檬酸、环己烷氨基磺酸、樟脑磺酸、天门冬氨酸、樟脑酸、葡萄糖酸、葡糖醛酸、谷氨酸、异抗坏血酸、乳酸、苹果酸、扁桃酸、焦谷氨酸、酒石酸、十二烷基硫酸、二苯甲酰酒石酸、乙烷-1,2-二磺酸、乙烷磺酸、蚁酸、富马酸、半乳糖酸、龙胆酸、戊二酸、2-酮戊二酸、乙醇酸、马尿酸、羟乙基磺酸、乳糖酸、抗坏血酸、天冬氨酸、月桂酸、樟脑酸、马来酸、丙二酸、甲磺酸、1,5-萘二磺酸、萘-2-磺酸、烟酸、油酸、乳清酸、草酸、棕榈酸、双羟萘酸、丙酸、水杨酸、4-氨基水杨酸、癸二酸、硬脂酸、丁二酸、硫氰酸、十一碳烯酸、三氟乙酸、苯磺酸、对甲基苯磺酸或L-苹果酸;n为0~3的整数;x为0~3的整数;且y为1~5的整数,优选为1~3的整数,更优选为1。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,R 1和R 1’选自氢、C 1-6烷基、C 1-6羟烷基、C 1-6卤代烷基、C 1-6烷氧基、3-8元杂环基、-(CH 2) nOR cc或-CR aaR bbOR cc,优选氢、C 1-3烷基、C 1-3羟烷基、C 1-3卤代烷基、C 1-3烷氧基、3-6元杂环基、-(CH 2) nOR cc或-CR aaR bbOR cc,更优选氢、甲基、乙基、丙基、异丙基、甲氧基、乙氧基、丙氧基、氟甲基、氟乙基、氟丙基、氯甲基、氯乙基、氯丙基、羟甲基、羟乙基、羟丙基、氧杂环丙基、氧杂环丁基、氧杂环戊基、氧杂环己基、氮杂环丙基、氮杂环丁基、氮杂环戊基、氮杂环己基、-CH 2OCH 3、-(CH 2) 2OCH 3、-CH(CH 3)OCH 3或-C(CH 3) 2OCH 3,进一步优选氢、甲基、甲氧基、异丙基、含氟甲基、羟甲基、氧杂环丁基、-CH 2OCH 3或-CH(CH 3)OCH 3。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,R 2选自氢、C 1-6烷基、卤素、氰基或-(CH 2) nOR cc,优选氢、C 1-3烷基、卤素、氰基或-(CH 2) nOR cc,更优选氢、甲基、乙基、丙基、甲氧基、乙氧基、丙氧基、氟、氯、溴或氰基,进一步优选氢、氟、甲基、甲氧基或氰基;或,任意两个相连的R 2形成一个取代或未取代的C 3-6环烷基或取代或未取代的3-6元杂环基,优选取代或未取代的C 3-6环烷基或取代或未取代的含1-3个选自N、O或S原子的3-6元杂环基,更优选环丙基、环丁基、环戊基、环己基、氧杂环丙基、氧杂环丁基、氧杂环戊基、氧杂环己基、氮杂环丙基、氮杂环丁基、氮杂环戊基、氮杂环己基,进一步优选环丁基、环戊基、1,3-二氧环戊基或1,3-二氧环己基。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,R 3和R 3’选自氢、C 1-6烷基、卤素、氰基或C 1-6烷氧基,优选氢、C 1-3烷基、卤素、氰基或C 1-3烷氧基,更优选氢、甲基、乙基、丙基、氟、氯、溴、氰基、甲氧基、乙氧基或丙氧基,进一步优选氢、氟、甲基、甲氧基或氰基;或,R 3和R 3’相连形成一个氧代基、C 3-6环烷基或3-6元杂环基,优选氧代基、C 3-6环烷基或含1-3个N、O或S原子的3-6元杂环基,更优选氧代基、环丙基、环丁基、环戊基、环己基、氧杂环丙基、氧杂环丁基、氧杂环戊基、氧杂环己基、氮杂环丙基、氮杂环丁基、氮杂环戊基或氮杂环己基,进一步优选氧代基、环丙基或氧杂环丁基。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,R 4选自氢、C 1-6烷基、卤素、氰基、C 1-6卤代烷基或C 3-8环烷基,优选氢、C 1-3烷基、卤素、氰基、C 1-3卤代烷基或C 3-6环烷基,更优选氢、甲基、乙基、丙基、氟、氯、溴、氰基、氟甲基、氟乙基、氯甲基、氯乙基、三氟甲基、三氟乙基、三氯甲基、三氯乙基、环丙基、环丁基、环戊基或环己基,进一步优选氢、氟、氯、甲基、三氟甲基、氰基或环丙基。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,R 5选自氢、C 1-6烷基或C 1-6卤代烷基,优选氢、C 1-3烷基或C 1-3卤代烷基,更优选氢、甲基、乙基、丙基、含氟甲基、含氟乙基、含氟丙基、含氯甲基、含氯乙基或含氯丙基,进一步优选氢或甲基;或者,R 1或R 1’与R 5相连形成3-6元杂环基,任选被氟、氯、溴、甲基、乙基或丙基的一个或多个取代基取代,优选氮杂环丙基、氮杂环丁基、氮杂环戊基、氮杂环己基、氟取代氮杂环丙基、氟取代氮杂环丁基、氟取代氮杂环戊基、氟取 代氮杂环己基、甲基取代的氮杂环丙基、甲基取代的氮杂环丁基、甲基吡咯烷基或甲基取代的氮杂环己基,进一步优选氮杂环丁基、氮杂环戊基或甲基吡咯烷基。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,R aa、R bb和R cc各自独立地选自氢、C 1-6烷基、C 1-6烷氧基、C 3-8环烷基或3-8元杂环基,优选氢、C 1-3烷基、C 1-3烷氧基、C 3-6环烷基或含1-3个N、O或S原子的3-6元杂环基,更优选氢、甲基、乙基、丙基、甲氧基、乙氧基、丙氧基、环丙基、环丁基、环戊基、环己基、氧杂环丙基、氧杂环丁基、氧杂环戊基或氧杂环丁基,进一步优选氢、甲基、乙基、异丙基、甲氧基、环丙基或氧杂环丁基。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,M选自硫酸、磷酸、苯磺酸、肉桂酸、酒石酸、乙烷-1,2-二磺酸、乙烷磺酸、富马酸或甲磺酸,优选硫酸、酒石酸、乙烷-1,2-二磺酸、乙烷磺酸、富马酸或甲磺酸,更优选硫酸、乙烷-1,2-二磺酸、乙烷磺酸或甲磺酸,进一步优选乙烷磺酸。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,W为-O-。
- 根据权利要求3所述的通式(I)所示的酸加成盐,其特征在于,G为-O-或-S-。
- 根据权利要求4所述的通式(I)所示的酸加成盐,其特征在于,R 5为氢。
- 根据权利要求5所述的通式(I)所示的酸加成盐,其特征在于,R 1’和R 3’为氢。
- 根据权利要求1所述的通式(I)所示的酸加成盐,其特征在于,所述酸加成盐为(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺的乙烷磺酸盐、甲磺酸盐或硫酸盐。
- 一种制备权利要求1-16任意一项所述酸加成盐的方法,具体包括如下步骤:1)称取化合物自由碱,加入有机溶剂,得到澄清或者混悬储备液;2)将酸M加入有机溶剂或水中,得到反离子酸溶液;3)将反离子酸溶液加入到储备液中,得盐溶液,搅拌析出固体并干燥;优选地,步骤1)或2)的有机溶剂选自醇类、酯类、烃类、酮类、醚类、苯类、酰胺类或腈类中的一种或多种,优选甲醇、乙醇、异丙醇、叔丁醇、乙酸乙酯、正己烷、庚烷、二氯甲烷、氯仿、四氯化碳、二氯乙烷、丙酮、2-丁酮、3-戊酮、异丙醚、石油醚、甲基叔丁基醚、四氢呋喃、1,4-二氧六环、苯、甲苯、N,N-二甲基甲酰胺或乙腈中的一种或多种,更优选甲醇、乙醇、异丙醇、乙酸乙酯、丙酮、二氯甲烷或乙腈中的一种或多种,进一步优选甲醇、乙醇、异丙醇、丙酮或乙腈中的一种或多种。
- 根据权利要求1-16任意一项所述的通式(I)所示的酸加成盐,其特征在于,式(I)所示的酸加成盐为晶型或无定型。
- 根据权利要求1-16任意一项所述的通式(I)所示的酸加成盐,其特征在于,式(I)所示的酸加成盐为水合物或无水物,优选无水物。
- 根据权利要求18所述的通式(I)所示的酸加成盐的晶型,其为(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺的乙烷磺酸盐晶型A,其X-射线粉末衍射图谱包含2θ为6.8±0.2°和13.4±0.2°、14.7±0.2°和19.5±0.2°、20.1±0.2°、23.9±0.2°、24.4±0.2°、25.0±0.2°、23±0.2°、23.6±0.2°、9.3±0.2°和17.3±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱包含2θ为6.8±0.2°、13.4±0.2°、14.7±0.2°和19.5±0.2°中的两处或三处衍射峰,任选的进一步还包含2θ为20.1± 0.2°、23.9±0.2°、24.4±0.2°、25.0±0.2°、23±0.2°、23.6±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条、5条或6条;例如,其X-射线粉末衍射图谱在13.4±0.2°、14.7±0.2°、19.5±0.2°、20.1±0.2°、23±0.2°、23.9±0.2°、24.4±0.2°和25.0±0.2处有特征峰;其X-射线粉末衍射图谱在6.8±0.2°、13.4±0.2°、14.7±0.2°、19.5±0.2°、20.1±0.2°、23.9±0.2°、23±0.2°和23.6±0.2°处有特征峰;其X-射线粉末衍射图谱在6.8±0.2°、13.4±0.2°、14.7±0.2°、19.5±0.2°、20.1±0.2°、23.9±0.2°、24.4±0.2°和25.0±0.2处有特征峰;其X-射线粉末衍射图谱在6.8±0.2°、13.4±0.2°、14.7±0.2°、19.5±0.2°、20.1±0.2°、23.9±0.2°、24.4±0.2°、25.0±0.2°、23±0.2°和23.6±0.2°处有特征峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺甲磺酸盐晶型A,其X-射线粉末衍射图谱在2θ为6.1±0.2°、7.5±0.2°、8.0±0.2°、14.9±0.2°、23.8±0.2°、8.4±0.2°、18.8±0.2°、20.7±0.2°、22.3±0.2°、22.8±0.2°、处具有衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱包含2θ为6.1±0.2°、7.5±0.2°和8.0±0.2°中的两处或三处衍射峰,任选的进一步还包含2θ为14.9±0.2°、18.8±0.2°、20.7±0.2°、22.3±0.2°、22.8±0.2°和23.8±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条、5条或6条;例如,其X-射线粉末衍射图谱在6.1±0.2°、7.5±0.2°、8.0±0.2°、14.9±0.2°、18.8±0.2°、22.3±0.2°、22.8±0.2°和23.8±0.2°处有特征峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺甲磺酸盐晶型B,其X-射线粉末衍射图谱在2θ为24.4±0.2°、13.3±0.2°、23.8±0.2°、20.3±0.2°、19.7±0.2°、17.2±0.2°、26.7±0.2°、9.0±0.2°、23.1±0.2°、9.9±0.2°、14.3±0.2°和21.6±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱在24.4±0.2°、13.3±0.2°和23.8±0.2°中的两处或三处衍射峰,任选的进一步包含2θ为9.0±0.2°、9.9±0.2°、26.7±0.2°、17.2±0.2°和23.1±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条或5条;例如,其X-射线粉末衍射图谱在24.4±0.2°、13.3±0.2°、23.8±0.2°、9.0±0.2°、9.9±0.2°、26.7±0.2°、17.2±0.2°和23.1±0.2°处有特征峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二 氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺甲磺酸盐晶型C,其X-射线粉末衍射图谱在2θ为22.5±0.2°、8.5±0.2°、7.2±0.2°、14.4±0.2°、26.7±0.2°、25.3±0.2°、12.8±0.2°、16.7±0.2°、6.1±0.2°、12.1±0.2°、15.2±0.2°和22.0±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱在2θ为22.5±0.2°、8.5±0.2°和7.2±0.2°中的两处或三处衍射峰,任选的进一步包含2θ为14.4±0.2°、26.7±0.2°、12.8±0.2°、16.7±0.2°和6.1±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条或5条;例如,其X-射线粉末衍射图谱在2θ为22.5±0.2°、8.5±0.2°、7.2±0.2°、14.4±0.2°、26.7±0.2°、12.8±0.2°、16.7±0.2°和6.1±0.2°处有特征峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型A,其X-射线粉末衍射图谱在2θ为8.4±0.2°、7.2±0.2°、20.1±0.2°、22.7±0.2°、24.5±0.2°、25.7±0.2°、18.9±0.2°、26.7±0.2°、16.4±0.2°、18.2±0.2°、22.0±0.2°和12.6±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱在2θ为8.4±0.2°、7.2±0.2°和20.1±0.2°中的两处或三处衍射峰,任选的进一步包含2θ为22.7±0.2°、24.5±0.2°、25.7±0.2°、18.9±0.2°和16.4±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条或5条;例如,其X-射线粉末衍射图谱在2θ为8.4±0.2°、7.2±0.2°、20.1±0.2°、22.7±0.2°、24.5±0.2°、25.7±0.2°、18.9±0.2°和16.4±0.2°处有衍射峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型B,其X-射线粉末衍射图谱在2θ为4.8±0.2°、7.6±0.2°、12.2±0.2°、14.0±0.2°、18.5±0.2°、22.9±0.2°、23.8±0.2°和24.9±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处或8处有衍射峰;例如,其X-射线粉末衍射图谱在2θ为4.8±0.2°、7.6±0.2°、12.2±0.2°、14.0±0.2°、18.5±0.2°、22.9±0.2°、23.8±0.2°和24.9±0.2°处有衍射峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型C,其X-射线粉末衍射图谱在2θ为24.5±0.2°、13.3±0.2°、23.9±0.2°、9.0±0.2°、17.3±0.2°、19.4±0.2°、26.9±0.2°、20.4±0.2°、17.7±0.2°、9.9±0.2°、20.0±0.2°和28.3±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2 处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱在2θ为24.5±0.2°、13.3±0.2°和23.9±0.2°中的两处或三处衍射峰,任选的进一步包含2θ为9.0±0.2°、17.3±0.2°、19.4±0.2°、17.7±0.2°和9.9±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条或5条;例如,其X-射线粉末衍射图谱在2θ为24.5±0.2°、13.3±0.2°、23.9±0.2°、9.0±0.2°、17.3±0.2°、19.4±0.2°、17.7±0.2°和9.9±0.2°处有衍射峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型D,其X-射线粉末衍射图谱在2θ为7.6±0.2°、22.5±0.2°、8.9±0.2°、15.0±0.2°、23.9±0.2°、26.6±0.2°、24.6±0.2°、5.8±0.2°、12.9±0.2°、19.9±0.2°、20.7±0.2°和11.6±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱在2θ为7.6±0.2°、22.5±0.2°和8.9±0.2°中的两处或三处衍射峰,任选的进一步包含2θ为15.0±0.2°、26.6±0.2°、5.8±0.2°、12.9±0.2°和11.6±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条或5条;例如,其X-射线粉末衍射图谱在2θ为7.6±0.2°、22.5±0.2°、8.9±0.2°、15.0±0.2°、26.6±0.2°、5.8±0.2°、12.9±0.2°和11.6±0.2°处有衍射峰;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型E,其X-射线粉末衍射图谱在2θ为17.7±0.2°、23.5±0.2°、24.8±0.2°、9.9±0.2°、22.6±0.2°、21.2±0.2°、19.1±0.2°、29.4±0.2°、16.9±0.2°、28.4±0.2°、17.3±0.2°和24.5±0.2°中的一处或多处衍射峰;优选的,包含其中任选的2处、4处、6处、8处或10处有衍射峰;或者,其X-射线粉末衍射图谱在2θ为17.7±0.2°、23.5±0.2°和24.8±0.2°中的两处或三处衍射峰,任选的进一步包含2θ为9.9±0.2°、22.6±0.2°、21.2±0.2°、19.1±0.2°和29.4±0.2°中的一处或多处衍射峰;优选包含其中2条、3条、4条或5条;例如,其X-射线粉末衍射图谱在2θ为17.7±0.2°、23.5±0.2°、24.8±0.2°、9.9±0.2°、22.6±0.2°、21.2±0.2°、19.1±0.2°和29.4±0.2°处有衍射峰。
- 根据权利要求18所述的通式(I)所示的酸加成盐的晶型,其为(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺的乙烷磺酸盐晶型A,其X-射线粉末衍射图谱在2θ为6.8±0.2°、9.3±0.2°、13.4±0.2°和14.7±0.2°处具有衍射峰;优选地,还包含在2θ为17.3±0.2°、19.5±0.2°、20.8±0.2°、23.9±0.2°和25.0±0.2°处具有衍射峰;更优选地,还包含在2θ为9.8±0.2°、18.4±0.2°、19.1±0.2°、20.1±0.2°、23.0±0.2°、23.6±0.2°、24.4±0.2°、27.3±0.2°和30.7±0.2°处具有衍射峰;进一步优选地,还包含在2θ为10.5±0.2°、17.5±0.2°、26.9±0.2°、27.7±0.2°、28.6±0.2°、29.6±0.2°、35.7±0.2°和37.6±0.2°处具有衍射峰;或者,其X-射线粉末衍射图谱在2θ为6.8±0.2°和13.4±0.2°处具有衍射峰;优选地,还包含在2θ为14.7±0.2°和19.5±0.2°中的一处或两处具有衍射峰;更优选地,还包含在2θ(±0.2°)为20.1±0.2°、23.9±0.2°、24.4±0.2°和25.0±0.2°中的一处或多处处具有衍射峰;进一步优选地,还包含在23±0.2°和23.6±0.2°中的一处或两处具有衍射峰;进一步优选地,还包含在9.3±0.2°和17.3±0.2°中的一处或两处具有衍射峰;再进一步优选地,还包含在2θ为9.8±0.2°、18.4±0.2°、19.1±0.2°、23.6±0.2°、27.3±0.2°和30.7±0.2°处具有衍射峰;再进一步优选还包含在2θ为10.5±0.2°、17.5±0.2°、26.9±0.2°、27.7±0.2°、28.6±0.2°、29.6±0.2°、35.7±0.2°和37.6±0.2°处具有衍射峰;最优选其X-射线粉末衍射图谱基本如图1所示;优选地,其TGA图谱基本如图2所示;更优选地,其DSC图谱基本如图3所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺甲磺酸盐晶型A,其X-射线粉末衍射图谱在2θ为6.1±0.2°和8.0±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为6.1±0.2°、7.5±0.2°、8.0±0.2°、14.9±0.2°和23.8±0.2°处具有衍射峰;更优选地,还包含在2θ为8.4±0.2°、18.8±0.2°、20.7±0.2°、22.3±0.2°和22.8±0.2°处具有衍射峰;进一步优选还包含在2θ为13.5±0.2°和25.2±0.2°处具有衍射峰;更进一步优选其X-射线粉末衍射图谱基本如图4所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺甲磺酸盐晶型B,其X-射线粉末衍射图谱在2θ为13.3±0.2°和23.1±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为9.0±0.2°、13.3±0.2°、19.7±0.2°和23.1±0.2°处具有衍射峰;更优选地,还包含在2θ为9.9±0.2°、17.2±0.2°、20.3±0.2°和26.7±0.2°处具有衍射峰;进一步优选地,还包含在2θ为14.3±0.2°、21.6±0.2°、23.8±0.2°和28.4±0.2°处具有衍射峰;更进一步优选地,还包含在2θ为24.4±0.2°、30.5±0.2°和32.6±0.2°处具有衍射峰;最优选其X-射线粉 末衍射图谱基本如图5所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺甲磺酸盐晶型C,其X-射线粉末衍射图谱在2θ为7.2±0.2°和22.5±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为7.2±0.2°、14.4±0.2°、22.5±0.2°和26.7±0.2°处具有衍射峰;更优选地,还包含在2θ为6.1±0.2°、12.8±0.2°、16.7±0.2°和20.8±0.2°处具有衍射峰;进一步优选地,还包含在2θ为8.5±0.2°、15.2±0.2°、22.0±0.2°和25.3±0.2°处具有衍射峰;更进一步优选地,还包含在2θ为12.1±0.2°、19.1±0.2°和23.8±0.2°处具有衍射峰;最优选其X-射线粉末衍射图谱基本如图6所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型A,其X-射线粉末衍射图谱在2θ为、8.4±0.2°和20.1±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为7.2±0.2°、8.4±0.2°、20.1±0.2°和22.7±0.2°处具有衍射峰;更优选地,还包含在2θ为5.8±0.2°、16.4±0.2°、18.9±0.2°和26.7±0.2°处具有衍射峰;进一步优选地,还包含在2θ为12.6±0.2°、14.7±0.2°、17.2±0.2°和25.1±0.2°处具有衍射峰;更进一步优选地,还包含在2θ为14.4、±0.2°18.2±0.2°、24.5±0.2°和25.7±0.2°处具有衍射峰;最优选其X-射线粉末衍射图谱基本如图7所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型B,其X-射线粉末衍射图谱在2θ为4.8±0.2°和7.6±0.2°处具有衍射峰;优选地,还包含在2θ为12.2±0.2°、14.0±0.2°、18.5±0.2°、22.9±0.2°和23.8±0.2°处具有衍射峰;更优选其X-射线粉末衍射图谱基本如图8所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型C,其X-射线粉末衍射图谱在2θ为13.3±0.2°和24.5±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为9.0±0.2°、13.3±0.2°、17.3±0.2°和24.5±0.2°处具有衍射峰;更优选地,还包含在2θ为9.9±0.2°、17.7±0.2°、19.4±0.2°和26.9±0.2°处具有衍射峰;进一步优选地,还包含在2θ为14.3±0.2°、18.6±0.2°、28.3±0.2°和37.5±0.2°处具有衍射峰;更进一步优选地,还包含在2θ为16.7±0.2°、20.0±0.2°、20.4±0.2°、24.0±0.2°和30.4±0.2°处具有衍射峰;最优选其X-射线粉末衍射图谱基本如图9所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型D,其X-射线 粉末衍射图谱在2θ为7.6±0.2°和15.0±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为7.6±0.2°、15.0±0.2°、22.5±0.2°和23.9±0.2°处具有衍射峰;更优选地,还包含在2θ为5.8±0.2°、12.9±0.2°、19.9±0.2°和26.6±0.2°处具有衍射峰;进一步优选地,还包含在2θ为8.9±0.2°、16.8±0.2°、20.7±0.2°和24.6±0.2°处具有衍射峰;更进一步优选地,还包含在2θ为10.1±0.2°、11.6±0.2°、17.4±0.2°、18.2±0.2°、19.1±0.2°、21.9±0.2°、25.4±0.2°和27.7±0.2°处具有衍射峰;最优选其X-射线粉末衍射图谱基本如图10所示;所述的晶型为化合物(S)-2-((2-((R)-4-(二氟甲基)-2-羰基噻唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英-9-基)氨基)丙酰胺硫酸盐晶型E,其X-射线粉末衍射图谱在2θ为9.9±0.2°和22.6±0.2°处具有衍射峰;优选地,其X-射线粉末衍射图谱在2θ为9.9±0.2°、17.7±0.2°、22.6±0.2°和24.8±0.2°处具有衍射峰;更优选地,还包含在2θ为16.9±0.2°、21.2±0.2°、23.5±0.2°和29.4±0.2°处具有衍射峰;进一步优选地,还包含在2θ为17.3±0.2°、19.1±0.2°、28.4±0.2°和30.5±0.2°处具有衍射峰;更进一步优选地,还包含在2θ为14.1±0.2°、16.2±0.2°、19.6±0.2°、20.7±0.2°、24.5±0.2°和26.5±0.2°处具有衍射峰;最优选其X-射线粉末衍射图谱基本如图11所示。
- 一种制备权利要求18-21任一项所述的晶型的方法,具体包括如下步骤:1)称取适量的自由碱,用不良性溶剂混悬;2)称取适量的酸M,用有机溶剂溶解;3)将2)中溶液加入1)中混悬液,搅拌析出固体;4)任选地,向步骤3)所得的固体中加入有机溶剂,搅拌析晶;5)搅拌、降温析晶得到目标产物;优选地,所述的不良性溶剂选自醇类、酯类、酮类、醚类、苯类、酰胺类或腈类中的一种或多种,优选甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、乙酸乙酯、丙酮、2-丁酮、四氢呋喃、1,4-二氧六环、苯、甲苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺或乙腈中的一种或多种,更优选甲醇、乙醇、异丙醇、四氢呋喃、乙酸乙酯、乙腈或丙酮中的一种或多种,进一步优选甲醇、乙醇、异丙醇、四氢呋喃、乙酸乙酯、乙腈或88%丙酮中的一种或多种;优选地,所述步骤2)的有机溶剂选自醇类、酯类、烃类、酮类、醚类、苯类、酰胺类或腈类中的一种或多种,优选甲醇、乙醇、异丙醇、叔丁醇、乙酸乙酯、二氯甲烷、氯仿、四氯化碳、二氯乙烷、正己烷、庚烷、丙酮、2-丁酮、3-戊酮、石油醚、四氢呋喃、甲基叔丁基醚、异丙醚、1,4-二氧六环、苯、甲苯、N,N-二甲基甲酰胺或乙腈中的一种或多种,更优选甲醇、乙醇、异丙醇、叔丁 醇、丙酮、四氢呋喃、甲苯、N,N-二甲基甲酰胺或乙腈中的一种或多种,更优选甲醇、乙醇、异丙醇、丙酮或乙腈中的一种或多种;优选地,所述步骤4)中有机溶剂选自醇类、酯类或醚类中的一种或多种,更优选甲醇、乙醇、正丙醇、异丙醇、乙酸乙酯、石油醚、甲基叔丁基醚、四氢呋喃或1,4-二氧六环中的一种或多种,进一步优选甲醇、乙醇、正丙醇、异丙醇、乙酸乙酯、甲基叔丁基醚或四氢呋喃中的一种或多种,更进一步优选甲醇、乙醇、异丙醇、乙酸乙酯或甲基叔丁基醚中的一种或多种。
- 一种制备权利要求18-21任一项所述的晶型的方法,具体包括如下步骤:1)称取适量的化合物盐,用不良溶剂混悬;2)振摇以上所得混悬液;3)将以上混悬液离心,去除上清液,剩余固体真空干燥得到目标产物;优选地,所述的不良性溶剂选自醇类、酮类、酯类、醚类、苯类、酰胺类或腈类中的一种或多种,优选甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、丙酮、2-丁酮、乙酸乙酯、四氢呋喃、1,4-二氧六环、苯、甲苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺或乙腈中的一种或多种,更优选甲醇、乙醇、正丙醇、异丙醇、丙酮或乙腈中的一种或多种,进一步优选甲醇、乙醇、正丙醇、异丙醇、88%丙酮或乙腈中的一种或多种。
- 一种制备权利要求18-21任一项所述的晶型的方法,具体包括如下步骤:称取适量化合物的盐,将化合物的盐暴露在一定湿度下放置一定时间;优选地,所述湿度为RH=70%~95%,优选RH=75%~95%,更优选RH=80%~95%,进一步优选RH=92.5%;时间1h~3天,优选1h~2天,更优选1h~1天,进一步优选3h。
- 一种制备权利要求18-21任一项所述的晶型的方法,具体包括如下步骤:1)称取适量的自由碱,用不良性溶剂混悬;2)称取适量的酸M,用有机溶剂溶解;3)将2)中溶液加入1)中混悬液,加热反应;4)任选地,向步骤3)溶液中加入有机溶剂;5)任选地,向步骤4)适量化合物的盐;6)降温析晶;优选地,所述的不良性溶剂选自醇类、酮类、酯类、醚类、苯类、酰胺类或乙腈中的一种或多种,优选甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、丙酮、2-丁酮、乙酸乙酯、四氢呋喃、1,4-二氧六环、苯、甲苯、N,N- 二甲基甲酰胺、N,N-二甲基乙酰胺或乙腈中的一种或多种,更优选甲醇、乙醇、正丙醇、异丙醇、丙酮或乙腈中的一种或多种;优选地,所述步骤2)中的有机溶剂选自醇类溶剂,优选甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇或叔丁醇中的一种或多种,优选甲醇、乙醇、异丙醇或叔丁醇中的一种或多种;优选地,所述步骤3)中的加热温度为30-80℃;优选地,所述步骤4)中的有机溶剂选自醇类、酯类或醚类中的一种或多种,优选甲醇、乙醇、正丙醇、异丙醇、乙酸乙酯、石油醚、甲基叔丁基醚、四氢呋喃或1,4-二氧六环中的一种或多种,更优选甲醇、乙醇、正丙醇、异丙醇、乙酸乙酯、甲基叔丁基醚或四氢呋喃中的一种或多种,进一步优选甲醇、乙醇、异丙醇、乙酸乙酯或甲基叔丁基醚中的一种或多种。
- 一种药物组合物,其含有治疗有效量的权利要求1-16中任一项所述的酸加成盐或者权利要求18-21所述的晶型,以及一种或多种药学上可接受的载体或赋形剂。
- 根据权利要求1-16任意一项所述的酸加成盐、权利要求18-20所述的晶型以及权利要求27所述的药物组合物在制备PI3K抑制剂药物中的应用,优选在制备PI3Kα抑制剂药物中的应用。
- 根据权利要求28所述的应用,其中所述的应用为在制备治疗癌症、骨病、炎性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸性疾病和心脏病中的药物应用;其中所述癌症选自乳腺癌、胰腺癌、非小细胞肺癌、甲状腺癌、精原细胞瘤、黑素瘤、膀胱癌、肝癌、肾癌、骨髓增生异常综合征、急性髓性白血病和结直肠癌。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080007242.7A CN113227101A (zh) | 2019-11-25 | 2020-11-19 | 含三并环类衍生物的盐或晶型及其药物组合物 |
JP2022528680A JP2023503010A (ja) | 2019-11-25 | 2020-11-19 | 3種類の縮合環誘導体含有塩又は結晶形態及びその医薬組成物 |
US17/777,966 US20230014383A1 (en) | 2019-11-25 | 2020-11-19 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
CA3159094A CA3159094A1 (en) | 2019-11-25 | 2020-11-19 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
AU2020389670A AU2020389670A1 (en) | 2019-11-25 | 2020-11-19 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
KR1020227020454A KR20220119610A (ko) | 2019-11-25 | 2020-11-19 | 3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물 |
EP20893659.1A EP4067363A4 (en) | 2019-11-25 | 2020-11-19 | SALT OR CRYSTAL FORM HAVING THREE CONDENSED RINGS AND PHARMACEUTICAL COMPOSITION THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911168310.3 | 2019-11-25 | ||
CN201911168310 | 2019-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021104146A1 true WO2021104146A1 (zh) | 2021-06-03 |
Family
ID=76130242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/130035 WO2021104146A1 (zh) | 2019-11-25 | 2020-11-19 | 含三并环类衍生物的盐或晶型及其药物组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230014383A1 (zh) |
EP (1) | EP4067363A4 (zh) |
JP (1) | JP2023503010A (zh) |
KR (1) | KR20220119610A (zh) |
CN (1) | CN113227101A (zh) |
AU (1) | AU2020389670A1 (zh) |
CA (1) | CA3159094A1 (zh) |
TW (1) | TW202120515A (zh) |
WO (1) | WO2021104146A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022161347A1 (zh) * | 2021-01-29 | 2022-08-04 | 南京明德新药研发有限公司 | 三并环类化合物及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010029082A1 (en) | 2008-09-10 | 2010-03-18 | Novartis Ag | Organic compounds |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
CN102762576A (zh) * | 2009-09-28 | 2012-10-31 | 霍夫曼-拉罗奇有限公司 | 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法 |
CN103562210A (zh) * | 2011-03-21 | 2014-02-05 | 弗·哈夫曼-拉罗切有限公司 | 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法 |
CN107873032A (zh) * | 2015-07-02 | 2018-04-03 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
CN107995911A (zh) * | 2015-07-02 | 2018-05-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
WO2018197653A1 (en) * | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
CN110088111A (zh) * | 2016-12-15 | 2019-08-02 | 豪夫迈·罗氏有限公司 | (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂卓-9-基)氨基)丙酰胺的制备方法 |
-
2020
- 2020-11-19 AU AU2020389670A patent/AU2020389670A1/en active Pending
- 2020-11-19 TW TW109140542A patent/TW202120515A/zh unknown
- 2020-11-19 CN CN202080007242.7A patent/CN113227101A/zh active Pending
- 2020-11-19 CA CA3159094A patent/CA3159094A1/en active Pending
- 2020-11-19 JP JP2022528680A patent/JP2023503010A/ja active Pending
- 2020-11-19 WO PCT/CN2020/130035 patent/WO2021104146A1/zh unknown
- 2020-11-19 EP EP20893659.1A patent/EP4067363A4/en active Pending
- 2020-11-19 US US17/777,966 patent/US20230014383A1/en active Pending
- 2020-11-19 KR KR1020227020454A patent/KR20220119610A/ko unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010029082A1 (en) | 2008-09-10 | 2010-03-18 | Novartis Ag | Organic compounds |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
CN102762576A (zh) * | 2009-09-28 | 2012-10-31 | 霍夫曼-拉罗奇有限公司 | 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法 |
CN103562210A (zh) * | 2011-03-21 | 2014-02-05 | 弗·哈夫曼-拉罗切有限公司 | 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法 |
CN107873032A (zh) * | 2015-07-02 | 2018-04-03 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
CN107995911A (zh) * | 2015-07-02 | 2018-05-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
CN110088111A (zh) * | 2016-12-15 | 2019-08-02 | 豪夫迈·罗氏有限公司 | (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂卓-9-基)氨基)丙酰胺的制备方法 |
WO2018197653A1 (en) * | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
Non-Patent Citations (3)
Title |
---|
HAN CHONG; KELLY SEAN M.; CRAVILLION THERESA; SAVAGE SCOTT J.; NGUYEN TINA; GOSSELIN FRANCIS: "Synthesis of PI3K Inhibitor GDC-0077 Via a Stereocontrolled N-arylation of A-amino Acids", TETRAHEDRON, vol. 75, no. 32, 27 April 2019 (2019-04-27), pages 4351 - 4357, XP085743440, ISSN: 0040-4020, DOI: 10.1016/j.tet.2019.04.057 * |
See also references of EP4067363A4 |
TIMOTHY P. HEFFRON, ROBERT A. HEALD, CHUDI NDUBAKU, BINQING WEI, MARTIN AUGISTIN, STEVEN DO, KYLE EDGAR, CHARLES EIGENBROT, LORI F: "The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1, 2, 4-Triazol-5-yl)-5, 6-Dihydrobenzo[f]Imidazo[1, 2-d][1, 4]Oxazepin-9-yl)oxy)Propanamide", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 3, 11 February 2016 (2016-02-11), pages 985 - 1002, XP055296322, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01483 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022161347A1 (zh) * | 2021-01-29 | 2022-08-04 | 南京明德新药研发有限公司 | 三并环类化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20230014383A1 (en) | 2023-01-19 |
KR20220119610A (ko) | 2022-08-30 |
EP4067363A4 (en) | 2023-12-27 |
EP4067363A1 (en) | 2022-10-05 |
AU2020389670A1 (en) | 2022-05-19 |
TW202120515A (zh) | 2021-06-01 |
JP2023503010A (ja) | 2023-01-26 |
CA3159094A1 (en) | 2021-06-03 |
CN113227101A (zh) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11629148B2 (en) | Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors | |
CN110785423B (zh) | 含三并环类衍生物抑制剂、其制备方法和应用 | |
WO2013016999A1 (zh) | 杂芳基并嘧啶类衍生物、其制备方法和用途 | |
WO2021244634A1 (zh) | 咪唑并吡啶类化合物及其用途 | |
CN113493440A (zh) | 含氮杂芳类衍生物的盐及其晶型 | |
WO2022033562A1 (zh) | 用于治疗重症肺炎的jak抑制剂化合物 | |
WO2021104146A1 (zh) | 含三并环类衍生物的盐或晶型及其药物组合物 | |
TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
WO2020020385A1 (zh) | 含三并环类衍生物抑制剂、其制备方法和应用 | |
CN110066272B (zh) | 取代的苯并[d]咪唑类化合物及其药物组合物 | |
WO2022100738A1 (zh) | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 | |
CN115368378A (zh) | 取代的大环化合物及包含该化合物的组合物及其用途 | |
TW202229278A (zh) | 含氮雜環類衍生物的鹽、晶型及其製備方法和應用 | |
CN112830935B (zh) | 含三并环类衍生物自由碱的晶型及其药物组合物 | |
RU2800543C2 (ru) | Ингибитор, содержащий трициклическое производное, способ его получения и его применение | |
CN113493439B (zh) | 取代的丙烯酰胺衍生物及其组合物及用途 | |
WO2021238908A1 (zh) | 杂芳类衍生物的盐、晶型及其制备方法 | |
CN113336760B (zh) | 取代的酰胺衍生物及其组合物及用途 | |
CN113717194A (zh) | 杂芳类衍生物的盐及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20893659 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3159094 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022528680 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020389670 Country of ref document: AU Date of ref document: 20201119 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020893659 Country of ref document: EP Effective date: 20220627 |